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Abstract
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Indole-3-carbinol (13 C) is a naturally occurring plant alkaloid, found in
significant concentrations in cruciferous vegetables such as broccoli and Brussels
sprouts. 13C is an unstable compound that undergoes rapid oligomerization in an
acidic environment to form higher order condensation products (13C-ACPs), such
as 3-3 '-diindolylmethane (DIM). Both 13C and DIM are marketed as dietary
supplements and are under investigation as potential chemopreventive agents,
despite limited data on the effects of chronic exposure. Previous studies have
demonstrated that the chemopreventive potential of 13C and DIM in animal studies
is dependent on species, strain, tissue and timing of treatment relative to carcinogen
Redacted for privacyexposure, and long-term post-initiation exposure can even promote tumors. The
majority of biological effects from 13C are the result of the abilities DIM and other
13C-ACPs to bind to the aryl hydrocarbon receptor and the subsequent induction of
phase I and phase II enzymes. Phase I and phase II enzyme induction inmany
cases leads to protection from carcinogens by increasing the rate of metabolism and
excretion but in some cases enhances carcinogenicity by increasing the rate of
bioactivation. It has been demonstrated that modulation ofenzyme levels can also
result in altered metabolism of compounds that could affect efficacy and toxicity of
pharmaceuticals and xenobiotics. The current work utilizes chronic dietary 13C and
DIM exposures in rodent models to further elucidate the effect these compounds
might have on health, drug metabolism and carcinogenesis. The reduced weight of
Fischer 344 rats treated with 2500 ppm 13C for 1 yearmay be indicative of adverse
effects but toxicity was not confirmed by blood chemistry or histopathological
examination. Furthermore, no toxicity was observed after a comparable treatment
of Sprague-Dawley rats. As observed after acute and sub-chronicexposures to 13C
and DIM, we documented significant induction of cytochrome P450enzymes and a
related modification to drug metabolism in liver slice incubations. Evidence is also
provided that may suggest that tumor modulation in mice may occur throughan
estrogenic mechanism. Further studies should be completed to determine the
potential for similar responses in humans.©Copyright by Dustin A. Leibelt
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CHAPTER 1
INTRODUCTION
In 2002, 1.3 million new cases of cancer, along with 555,500 cancer deaths
were expected in the United States, and despite breakthroughs in early detection
and cancer treatment, the latest studies found that the 5year survival rate for all
cancers was only 62% (American Cancer Society, 2002). Statistics such as these
have driven research in cancer prevention over the last two decades.
In a landmark paper by Doll and Peto (1981) the first evidence suggestinga
strong association between dietary components and cancer risk was presented.
These epidemiology data, along with supporting animal studies (Rogerset al.,
1993), lead health authorities to make dietary recommendations to decreasecancer
risk (Bal and Foerster, 1991; Dwyer, 1993). In subsequent studies, epidemiological
data linked diets high in fruits and vegetables witha decrease in cancer incidence
(Blocket al.,1992; Steinmetz and Potter, 1996) and stimulated further research into
the area of phytochemicals and their ability to provide chemoprotection against
cancer (Greenwald and McDonald, 1997; Greenwald, 1999; and Kelloffet. al.,2000). This research has lead to the identification ofnumerous possible
chemopreventive agents, one of the most promising being indole-3-carbinol (13C).
13C is a naturally occurring plant alkaloid formed from the hydrolysis of
indole glucosinolate (glucobrassicin), found in significant concentrations in
cruciferous vegetables such as broccoli, cauliflower, and Brussels sprouts (Fenwick
et al.,1983; Slominski and Campbell, 1987; McDannellet al.,1988;
Preobrazhenskayaet al.,1993). Glucobrassicin is hydrolyzed to glucose, sulfate,
thiocyanate and 13C, via the intermediate 3-indolylmethyl isothiocyanate,upon
maceration or cutting of plant tissue at neutral pH, in thepresence of the enzyme
myrosinase (Figure 1.1).
13 C is a relatively unstable compound and can condense with itself to form
3,3'-diindolylmethane (DIM) or combine with L-ascorbic acid, which is also found
at high levels in cruciferous plants, to form ascorbigen (Figure 1.1). Inan acidic
environment, such as the stomach after oralexposure, 13C undergoes rapid
oligomerization to form dimers, trimers, tetramers, and several other higher order
condensation products (13C-ACP) (Figure 1.2) (Leete and Marion, 1953; Bradfield
and Bjeldanes, 1987; Bjeldaneset al.,1991; De Kruifet al.,1991; Grose and
Bjeldanes, 1992; Wortelboeret al.,1992). A number of these compounds have
been identified including 3,3' -diindolylmethane (DIM), 2-(indol-3-ylmethyl)-3 ,3 '-N-oso;
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Figure 1 .1: Enzymatic hydrolysis of glucobrassicin, found in cruciferous
vegetables, and formation of 13C. 1= Glucobrassicin; 2 = Tndole-3-acetonitrile; 3 =
3-Indolylmethyl isothiocyanate; 4Indole-3-carbinol(13C); 5 = Ascorbigen; 6
3,3'- Diindolylmethane (DIM) (from McDanellet al., 1988).
diindolylmethane (linear trimer or LT1), 5,6,11,12,17,1 8-hexahydrocyclonona[ 1,2-
b:4,5-b':7,8-b"]triindole (cyclic trimer or CT) and indolo[3,2-bjcarbazole (ICZ).
The major product formed in vitro (Spande, 1979) and in vivo after oral
administration (Dashwoodet al.,1989; Stresseret al.,1995a) is the dimer, DIM.
Most of what will be discussed in this thesis is in reference to the parent
compound 13C, but it must be kept in mind that 13C is inactive until formation ofOH
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Figure 1.2: Structure of 13C acid condensation products found in liver extracts of
rats given 13 C orally. 133', 3,3' -diindolylmethane; LT, [2-(indol-3-ylmethyl)--indol-
3 -yl]indol-3-ylmethane; HI-IM, (hydroxymethyl)indolyl-3-indolylmethane; CT,
5,6,1 1,12,17,18-hexahydroclonal[1,2-b:4,5-b':7,8-b]:triindole; ICZ, 3,2-b-
indolocarbazole. 13C itself was not detected in liver extracts. (Taken from Stresser
etal.,1995).
the above condensation products occurs. When administered iv and the stomach is
bypassed, the biological efficacy of 13C is eliminated. The explanation for this is
that the majority of 13C-ACP bind with relatively high affinity to the aryl
hydrocarbon receptor (AHR) when compared to the parent compound (Kjs of 90,
20, 60 and 0.19 nM for DIM, LT1, CT, and ICZ, respectively compared to 0.007nM for TCDD and 27,000 nM for 13C) (Bjeldanes et al., 1991). The hypothesis
that the majority of effects elicited by 13Care actually actions of 13 C-ACP through
the AHR is relevant in that the levels of these derivatives in rat and trout liver tissue
after administration of 3H-13C were found to be in the tMrange (Dashwood et al.,
1989; Stresser etal., 1995a).
13C and DIM are now both made synthetically and marketedas dietary
supplements. 13C is also under evaluation for chemoprotection ofwomen against
breast cancer (Wong et al., 1997; Lawrence et al., 2000) and cervical dysplasia
(Bell et al., 2000). 13C has been in trials (Rosen etal., 1998) and both 13C and
DIM are utilized as treatments for recurrent respiratory papillomatosis (RRP).
Besides chemoprotection, their proposed health benefits include promoting
beneficial estrogen metabolism (Zeligs, 1999), providing antioxidant protection,
boosting the immune system, and actingas a phytochemical replacement for those
who lack cruciferous vegetables in their diet. 13C and DIMare rapidly becoming
two of the top selling phytochemical supplements.
13C and DIM in chemoprevention
By far the most researched area dealing with 13C and DIM is in
chemoprevention. In 1977 it was shown that oral administration of 13C and other
indoles prior to andlor with polycyclic aromatic hydrocarbons (PAHs)was
chemoprotective (Wattenberg, 1977). Since then, 13C and DIM have been shownto be chemoprotective in a number of animal modelsacross a variety of target
organs (Wattenberg and Loub, 1978; Morseet al.,1990; Baileyetal.,1991;
Kojimaet al.,1994; Grubbset al.,1995; Guoet al.,1995; Oganesianet al.,1997;
Chenet al.,1998; Mansonetal.,1998; Srivastava and Shukla, 1998; Jilletal.,
1999). 13C has also been shown to be effective againsta wide variety of
environmentally relevant chemical carcinogens including nitrosamines (Shertzer,
1984; Fong et al., 1988; Morse et al., 1988), PAHs (Shertzer, 1983; Jongenet al.,
1989) and mycotoxins like aflatoxinB1 (AFB1)(Nixonet al.,1984).
It has been proposed that the chemoprotection from 13C is most likely due
to a blocking mechanism. A blocking agent is a compound that inhibits
carcinogenesis by preventing the carcinogen from reachingor reacting with critical
target sites. The possible mechanisms behind this blocking action include (i)
induction of biotransformation enzymes that deactivateor enhance secretion of
carcinogens, (ii) inhibition of enzymes that bioactivate procarcinogens, and (iii)
physico-chemico interaction with carcinogen as in nucleophilic trapping of
electrophiles or complexing. There are examples in the literature of 13C
functioning by all three mechanisms.
Through 13C-ACP interactions with the AHR, 13C has been shown to actas
a blocking agent in animal models of cancer chemoprevention (Wortelboeret al.,
1992; Guoetal.,1995). The proposed mechanism of action involves induction of
phase I and phase II metabolizing enzymes that result in deactivationor increasedexcretion of carcinogens (Bjeldaneset al.,1991; Stresseret al.,1994a, 1994b). An
example of this is the shift that occursinAFB1metabolism after 13C exposure. The
induction of CYP1A in trout and rat by 13C directs metabolismaway from the
CYP2CI 1 and CYP3A mediated pathway of AFB1-8,9-epoxide production, which
is known to form adducts with DNA, and toward the formation of AFM1, which has
reduced carcinogenic potency (Cullenet al.,1987; Stresseret al.,1994a; Takahashi
et al.,1995). The phase II enzymes induced by 13C include UDP-glucuronosyl
transferase (UDPGT), glutathione S-transferase (GST) and NAD(P)H:quinone
oxidoreductase (NQO) (Shertzer and Sainsbury, 199 Ia). The phase IIenzymes act
by conjugating endogenous hydrophilic groups to xenobiotics leading to diminished
activity of activated procarcingens and increased excretion. Asan example, 13C
induces the Y2 isoform of glutathione S-transferase (GST) in the rat, which has
been shown to have a high activity towards AFB1-8,9-exo-epoxide, the ultimate
carcinogenic metabolite of AFB1 (Stresseret al.,1994b; Hayeset al.,1998).
An alternative blocking mechanism, involving inhibition of carcinogen
bioactivation, has been proposed based on data indicating that 13Ccan inhibit
DMBA inducedmammary tumorigenesis when given only four hours prior to the
carcinogen (Wattenberg, 1990). This proposal was supported by evidence thata
number of 13C-ACPs, including DIM, can inhibit the catalytic activity of CYP
(Stresseret al.,1995b). The K1of DIM inhibition of rat and human CYP 1A is 2-8
iM which is comparable to the concentration found in rat liver (3-6 pM) andhuman blood (0.4 1.6 tM) after oral dosing (Stresseretal., 1995a; Arnesonetal.,
1999). A decrease in CYP activity and the subsequent decrease in bio activation of
carcinogens also appears to be the primary mechanism of 13C protection in thetrout
model (Fongetal., 1990; Baileyetal., 1992).
A third blocking mechanism involves physico-chemical interaction with the
carcinogen. In many cases carcinogens are activated to electrophilic intermediates
that can directly bind to macromolecules like DNA. 13C and other indole
compounds have been shown to block damage to macromolecules through
antioxidant and radical scavenging properties (Shertzeretal., 1988; Wallinetal.,
1993) and contribute to chemoproventionas in the protection against
benzo[a]pyrene-induced skin tumors in mice (Shertzeretal., 1994).
In other cases the effects that enzyme induction by 13 C haveon
chemoprevention are indirect, as in the metabolism of estradiol by CYP's in the 1
family. CYP 1 Al and 1 A2 catalyze the 2-hydroxylation of -estradio1 (E2), whereas
CYP1B1 is an effective E2-4-hydroxylase (Hayesetal., 1996). While it appears
that both catechol estrogens are potentially toxic, evidence suggests that 4-OH-E2 is
the more reactive and toxic metabolite (Newbold and Liehr, 2000), and is less likely
to be detoxified through methylation by catechol 0-methyltransferase (COMT)
(Roy etal., 1990). The shift towards higher levels of 2-hydroxy-E2 that would
occur with induced CYP I Al levels may explain the chemoprotective effect
exhibited by 13 C or DIM against estrogen dependentcancers (Bradlowetal., 1991;Jellincket al.,1993; Telanget al.,1997; Wonget al.,1997; Michnovicz, 1998).
Clinical trials with 13C have documented reductions in urinaryE2levels in both
men and women concurrent with an increase in the2-OH-E2/16a-OH-E2ratio
(Michnoviczet al.,1997) and absorption-enhanced DIM also increased this ratio in
a pilot clinical study (Zeligset al.,2002).
Besides direct and indirect actions through the AHR already mentioned,
additional mechanisms have been postulated for chemoprevention by 13C, DIM,
and other 13C-ACP. 13C and/or 13C-ACP have been shown to inducea Gi cell
cycle arrest by down-regulating the expression of cyclin-dependent kinase-6 (Cover
et al.,1998). Tn other studies 13C and 13C-ACP have increased apoptosis inhuman
cancer cells (Geet al.,1996), inhibited in vivo P-glycoprotein-dependent multidrug
resistance (Christensen and LeBlanc, 1996), and inhibited invasion and migration
of breast tumor cells (Menget al.,2000). It has also been demonstrated that a
specific 13 C-ACP,LT1,inhibits proliferation of both estrogen-responsive and
estrogen-independent human breast cancer cell lines and functions bothas a weak
AHR agonist and an estrogen receptor (ER) antagonist (Chang et al., 1999).
13C and DIM in Tumor Promotion and Carcinoenesis
Despite the large number of examples where 13C and DIM playa role in
chernoprevention and the lack of data suggesting 13C is a complete carcinogen
(Dashwoodet al.,1991; Oganesianet al.,1999; Stoneret al.,2002), there is some10
evidence indicating exposure to 13Ccan increase cancer risk. Although induction
of enzymes make 13C effective as a blocking agent againstsome carcinogens, in
some cases enzyme induction is a cause for concern. Certain CYP isozymes,
especially those in the 1A subfamily,can enhance carcinogenicity by increasing the
rate of bioactiviation (loannides and Parke, 1993); for example the activation of
polycyclic aromatic hydrocarbons such as benzo[a]pyrene and aromatic amines
such as 4-aminobiphenyl or PhIP. Dietaryexposure to 13C elevated tumor
incidence in rats initiated with the colon-specific carcinogen 1 ,2-dimethylhydrazine
(1,2-DMH) apparently by enhancing carcinogen binding to DNA (Autrupet al.,
1980; Penceet al.,1986). DNA adduct levels were also elevated in the liver of rats
exposed to dietary 13C prior to intubation with the tobacco-specific nitrosamine 4-
(methylnitroarnino)- 1 -(3 -pyridyl)- 1 -butanone (NNK) (Morseet al.,1988). 13 C
exposure resulted in a significant increase in liver foci in rats initiated with
aflatoxinB1(Stoneret al.,2002) and was found to promote hepatocarcinogenesis in
trout (Dashwoodet al.,1991; Oganesianet al.,1999). The potential for
enhancement of tumorigenesis was also demonstrated ina study in which 13C
elevated I 2-0-tetradecanoyl phorbol- 13-acetate induction of ornithine
decarboxylase activity in mouse epidermis, signifying tumor promoting activity
(Birtet al.,1986).Some studies have even demonstrated that in the presence of
nitrites and acid, 13C and its ACPs can be converted to nitrosamines (Tiedinket al.,11
1989; Sasagawa and Matsushima, 1991). This suggests that under conditions found
in the stomach, 13C may indirectly contribute tocancer initiation.
In addition to the previously mentioned antiestrogenic effects thatseem to
contribute to chemoprevention, 13C and DIM have also been shown to exhibit
estrogenic activity in rainbow trout (Shilling and Williams, 2000; Shillinget al.,
2001). The estrogenicity of 13C is a likely mechanism by which 13C promotes
hepatocarcinogenesis in trout (Oganesian et al., 1999). DIM is primarilyan anti-
estrogen in mammals (Chen et al., 1998; McDougal et al., 2001) and it has been
proposed that this difference may bea function of species-specific DIM
metabolism. Preliminary evidence indicates that CYP-dependent hydroxylation of
DIM is required in trout to elicit estrogenicity (Shilling et al., 2001).
Toxicity Studies
13C does not exhibit obvious cytotoxicity (Babich et al., 1993)or
mutagenicity (Reddy et at., 1983; Birt etal., 1986; Kuo etal., 1992) in vitro, and
demonstrates relatively low acute toxicity and limited teratogenic effects in vivo
when administered orally (Nishie and Daxenbichler, 1980; Dashwoodet al., 1991;
Shertzer and Sainsbury, 1991 a). The LD50 in rat after oral dosingwas estimated to
be more than 2,250 mg/kg body weight ina study sponsored by the
Chemoprevention Branch of the National Cancer Institute (Nd).12
Conversely, in other NCI sponsored studies, several adverse effects of
chronic 13C exposure were revealed. Twenty-eight and 90-day feeding studieswere
performed in rats and dogs. Doses ranging from 20 to 2000 mg/kg body weight in
rats resulted in toxic effects to the hematopoietic system, liver, hair coat and testes,
and doses of 20 and 100 mg/kg body weight resulted inan increase in liver weight
associated with induction of smooth endoplasmic reticulum. In dogs, diarrheawas
observed in the 28- and 90-day studies after administration of 13C at 15 to 150
mg/kg body weight. The 150 mg/kg body weight dose also resulted in diminished
body weights, thymic atrophy, anemia and testicular degeneration (Kelloffet al.,
1996).
13C and DIM Effects on Xenobiotic Metabolism
One area of concern for chronic exposure to such phytochemicals is the well
documented occurrence of drug-drug interactionsas a result of phytochemical
induced modulation of metabolizingenzymes. The most prominent example
involves alteration of blood levels of drugs in patients consuming grapefruit juice
(Baileyet al.,1994). In this case furanocoumarins in the grapefruit juice inhibit
CYP3A4, a CYP isoform responsible for the metabolism of 5 0-60% of all
therapeutic drugs (Guengrich, 1999). This results inan improved bioavailability of
drugs such as midazolam, cyclosporine, and felodipine leading toan increase in13
efficacy or enhanced toxicity dependingon the pharmacological properties of the
metabolites and the therapeutic index.
The concerns over drug-drugor food-drug interactions via 13C and DIM
exposure are substantiated by data from previous studies demonstrating similar
enzyme interactions. As previously mentioned, induction of numerous CYP
isoforms resulting from dietary exposure of 13C and DIM in animals has been well
documented. Short term 13C exposure has produced 2-4 fold inductions of hepatic
CYP1A2, CYP2B1/2, and CYP3A with over 20-fold increases observed in
CYP1AI (Stresseret al.,1994a). Chronic exposures, as studied in the current work
(Ch 2 & 3), have resulted in even stronger 40- and 30- fold inductions for CYP1A1
and CYP3A2, respectively, depending on dose and strain of rat. Sub-chronic
exposures to 13C have also been shown to inhibit flavin-containing monooxygenase
(FMO) isoform 1 expression and activity in the rat liver and intestine ina time- and
dose-dependent fashion (Larsen-Su and Williams, 1996). For drugs metabolically
inactivated by FMO a trend of increasing efficacyor toxicity could occur with
increasing exposure to 13C or DIM, whereas the opposite couldoccur with CYP
induction as an increase in metabolism could lead to diminished potency.
The potential effects that the combined CYP induction and FMO inhibition
have on drug metabolism were documented by Katchamartet al.(2000). This
study demonstrated that the ratio of FMO/CYP mediated metabolism of N,N-
dimethylaniline, nicotine, and tamoxifen in incubations with liver microsomes14
decreased after rats were given 2500ppm DIM in their diets for 4 weeks. This
decrease in metabolite ratio was attributed toan inhibition of FMO-dependent
formation of the N-oxide of these tertiary amines witha concurrent induction of
CYP -mediated N-demethylation. The concurrent inductions of CYP and inhibition
of FMO raises concerns as to the effects 13 C and DIMmay have on the metabolism
of other drugs and xenobiotics.
Other Biological Effects
There is some evidence that 13C and DIM may have effectson the level and
activity of other proteins involved in essential metabolic functions. Dunn and
LeBlanc (1994) demonstrated that some acid condensation products of 13C lower
serum LDL/VLDL cholesterol levels in mice by inhibiting acyl-CoA:cholesterol
acyltransferase (ACAT). UDP-glucose dehydrogenase,a cytosolic enzyme
responsible for the formation of UDP-glucuronic acid, and NADPH-cytochromec-
reductase and cytochrome b5, proteins involved in microsomal electrontransport
and xenobiotic metabolism, were found to be elevated in rats exposed to 4100ppm
dietary 13C for 10 days (Cha et al., 1985). A decrease in activity of superoxide
dismutase and glutathione peroxidase was observed in rats that received 50 mg/kg
13C for 10 days by gavage (Shertzer and Sainsbury, 1991b). Long-term feeding of
0.5% 13C to rats was shown to inhibit ornithine decarboxylase (ODC) activity15
(Manson et al., 1998), the enzyme responsible for the rate limitingstep in
polyamine synthesis, which is required for DNA replication and cell proliferation.
13C and DIM Exposure Comparisons
It is very important to consider 13C and DIM dose when making
comparisons or extrapolations from observed data to real life situations. The
chronic doses of 13C and DIM utilized in the current studieswere selected to
provide data that would represent the current supplemental doses andnot dietary
exposures. The recommended maximum human doses of 13C and DIM are 10
mg/kg (Life ExtensionsTM) and 2 mg/kg (BioResponse, LLC), respectively. In
comparison, a 300 g serving of Brussels sprouts would provide between .29 and 2.1
mg/kg/day 13C.
Summary
Despite the increasing use of 13C and DIM as dietary supplements, andas
treatments for breast cancer, recurrent respiratory papillomatosis (RRP), and
cervical intraepithelial neoplasia (CIN), little is known about the effects of chronic
dietary exposure. The chemopreventive properties of the compounds have been
well documented and acute and sub-chronic studies have failed to reveal significant
toxicities. On the other hand, studies demonstrating the promotion ofcancer, the
lack of long-term exposure data and the observed alterations in CYP levels and16
drug metabolism raise concerns relative to chronicexposure of humans to these
compounds.17
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CHAPTER 2
Effects of Chronic Dietary Indole-3-Carbinol (13C) Exposure
On Blood Chemistry, Histopathology, and Cytochrome
P450 in Male Fischer 344 Rats
Dustin A. Leibelt, Olaf R. Hedstrom, Kay A. Fischer,
Clifford B. Pereira, and David E. Williams
Department of Environmental and Molecular Toxicology
Oregon State University, Corvallis, OR28
Abstract
Indole-3-carbinol (13C) is a naturally occurring component of the human
diet and is found in high concentrations in cruciferous vegetables. 13Cis also
marketed as a dietary supplement and has been proposedas a chemopreventive
agent for women against breast cancer. Acute and sub-chronicexposures of 13C
have failed to uncover significant toxicities in the rat but alterations in phase I and
phase II drug metabolizing enzymes have been observed. Long-term studies have
focused on the effects of chronic 13Cexposure on both chemoprevention and tumor
promotion. Less is known about the effects of long-term 13Cexposure on health
and drug/xenobiotic metabolism. Fischer 344 ratswere fed diets containing 0,
1000, or 2500 ppm 13C for either 6or 12 months. Gross pathology of the entire
animal along with histopathological examination of the liver, kidneys, adrenals,
colon, prostate, and testes yieldedno significant lesions in 13C treated rats. A small
animal chemistry panel was performed andserum testosterone levels determined.
The results of the chemistry panel did not indicateany level of toxicity, and in fact
there was a general trend of decreasingserum enzyme levels (aspartate
aminotransferase, alanine aminotransferase, alkaline phosphatase, creatine kinase)
with increasing 13C dose after 6 and 12 months. Testosterone levelswere slightly
reduced in the rat serum after 6 months, but significantly elevated after 12 months
of exposure. The only other significant findings in theserum analysis were an
increase in globulin levels after 6 months,an increase in amylase levels after 1229
months and a decrease in calcium levels also after 12 months. The total
cytochrome P450 (CYP) of the liver was determined along with the levels of the
specific isoforms CYP1A1/2 and CYP3A2. As seen in sub-chronic studies, the
liver total CYP content was significantly induced, as were CYP 1 A1/2 and CYP3A2
levels. While confirming that 13C is relatively non-toxic in the rat, the alterations
observed in this study following long-term dietary I3C administration raise
concerns relative to potential adverse effects on hormone levels and
drug/xenobiotic metabolism.30
Introduction
13C is a naturally occurring plant alkaloid formed from the hydrolysis of
indole glucosinolate (glucobrassicin), found in significant concentrationsin
cruciferous vegetables such as broccoli, cauliflower, and Brusselssprouts
(Slominski and Campbell, 1987; MeDaimellet al.,1988). Glucobrassicin is
hydrolyzed to glucose, sulfate, thiocyanate and 13Cupon maceration of plant tissue
at neutral pH, in the presence of the enzyme myrosinase. Even at neutral pH, 13C is
relatively unstable and readily condenses with itself to form 3,3' -diindolylmethane
(DIM) or combines with L-ascorbic acid, which is also foundat high levels in
cruciferous plants, to form ascorbigen. Inan acidic environment, such as the
stomach after oral exposure, 13C undergoes rapid oligomerization to form dimers,
trimers, tetramers, and several other higher order acid condensation products (13C-
ACP) (Bjeldaneset al.,1991; De Kruifet al.,1991; Grose and Bjeldanes, 1992;
Wortelboeret al.,1992). A number of these compounds have been identified
including 3,3' -diindolylmethane (DIM), 2-(indol-3-ylmethyl)-3 ,3 '-
diindolylmethane (linear trimer or LT1), 5,6,11,12,17,1 8-hexahydrocyclonona[ 1,2-
b:4,5-b':7,8-b"]triindole (cyclic trimer or CT) and indolo[3,2-b]carbazole (ICZ).
13C itself does not become biologically/pharmacologically active until the
above acid condensation productsare formed. In fact, when 13C is administered iv
and the stomach is bypassed, biological efficacy is eliminated. The explanation for
this is that the majority of 13 C-ACPs bind with relatively high affinityto the aryl31
hydrocarbon receptor (AHR) when compared to the parent compound(K1sof 90,
20, 60 and 0.19 nM for DIM, LT1, CT, and ICZ, respectively comparedto 0.007
nM for TCDD and 27,000 nM for 13C) (Bjeldanesetal., 1991). The hypothesis
that the majority of effects elicited by 13Care actually actions of 13C-ACP through
the AHR is relevant in that the levels of these derivatives in rat andtrout liver tissue
after administration of 3H-13C were found to be in the iMrange (Dashwoodetal.,
1989; Stresseretal., 1995).
Through 13C-ACP interactions with the AHR, 13C has been shown to actas
a blocking agent in animal models of cancer chemoprevention (Wortelboeretal.,
1992; Guoetal., 1995). The proposed mechanism of action involves AHR-
dependent induction of phase I and phase IIenzymes (Bjeldanesetal., 1991;
Stresseretal., 1994). The induction of phase I enzymes suchas CYP1A1/2,
CYP2B1/2, and CYP3A1/2 in manycases leads to protection from carcinogens by
increasing their rate of oxidative metabolism to less toxic metabolites thatare more
easily excreted. An example of this is the detoxification of aflatoxini(AFB') to
aflatoxinM1(AFM1) and aflatoxin Qi (AFQ1) by CYP1A and CYP3A, respectively
(Stresseretal., 1994).Phase II enzymes induced include UDP-glucuronosyl
transferase, glutathione S-transferase (GST) and NAD(P)H:quinone oxidoreductase
(Shertzer and Sainsbury, 1991). These phase IIenzymes act by adding endogenous
hydrophilic groups to xenobiotics leading to diminished activity of activated
procarcinogens and increased excretion.32
In some instances, induction of enzymescan be a cause for concern.
Certain CYP isozymes, especially in the 1A subfamily,can enhance carcinogenicity
by increasing the rate of bioactivation (Ioaimides and Parke, 1993); forexample the
activation of polycyclic aromatic hydrocarbons suchas benzo[a]pyrene and
aromatic amines such as 4-aminobiphenylor PulP.
In other cases the effects that enzyme induction hason carcinogenesis are
indirect, as in the metabolism of estradiol by CYPs in the 1 family.CYP1A1 and
1A2 catalyze the 2-hydroxylation of 13-estradiol (B2), whereas CYP1B1 isan
effective B2-4-hydroxylase (Hayesetal., 1996). While it appears that both catechol
estrogens are potentially toxic, evidence suggests that4-OH-E2is the more reactive
and toxic metabolite (Newbold and Liehr, 2000), and is less likelyto be detoxified
through methylation by catechol 0-methyltransferase (COMT) (Royetal., 1990).
The shift towards higher levels of2-hydroxy-E2that would occur with induced
CYP1A1 levels may explain the chemoprotective effect exhibited by 13Cor DIM
against estrogen dependent cancers (Bradlowetal., 1991; Jellincketal., 1993;
Telangetal., 1997; Wongetal., 1997; Michnoviczet al.,1998).
Although effective as a blocking agent, long-term post-initiationexposure to
13C, as would most likely occur in humans, has shown the potential topromote
hepatocarcinogenesis. Chronic 13C exposure resulted ina significant increase in
liver foci in rats initiated with aflatoxin B1 (Stoneret al.,2002) and was found topromote hepatocarcinogenesis in trout (Dashwoodet al.,1991; Oganesianet al.,
1999).
The health consequences of CYPenzyme induction are not limited to
33
carcinogen bioactivationldetoxificationor tumor promotion. Phase I enzymes such
as CYP 3A make up approximately 40% of the total hepatic CYP content in human
liver and play an important role in drug metabolismas 50-60% of all clinically
relevant drugs are metabolized by this subfamily (Guengrich, 1999). Asan
example of a potential 13 C-drug interaction, studies have shown differential
metabolism of tamoxifen and nicotine by liver microsomes from rats fed 13C
(Katchamartet al.,2000).
Despite the possible promotional properties and the potential effects 13C
could have on drug metabolism, little evidence of direct toxicity by 13C has been
uncovered. 13C does not exhibit obvious cytotoxicity (Babichet al.,1993) or
mutagenicity (Reddyet al.,1983; Birtet al.,1986; Kuoet al.,1992)in vitro,and
demonstrates relatively low acute toxicity and limited teratogenic effectsin vivo
when administered orally (Nishie and Daxenbichier, 1980; Dashwoodet al.,1991;
Shertzer and Sainsbury, 1991). TheLD50in rats after oral dosing was estimated to
be more than 2,250 mg/kg body weight ina study sponsored by the
Chemoprevention Branch of the National Cancer Institute (NCI).
Conversely, other NCI sponsored studies have revealed several adverse
effects of sub-chronic 13C exposure in rats and dogs. In rats, doses ranging from 2034
to 2000 mg/kg body weight resulted in toxic effects to the hematopoieticsystem,
liver, hair coat and testes, and doses of 20 and 100 mg/kg body weightresulted in
an increase in liver weight associated with induction of smooth endoplasmic
reticulum. A study in which prenatal 13Cexposure resulted in adverse reproductive
outcomes in male Sprague-Dawley rats is a notable exception to the normal absence
of teratogenic effects (Wilkeret al.,1996). In dogs, diarrhea was observed in 28-
and 90-day studies after administration of 15 to 150 mg/kg body weight. The 150
mg/kg body weight dose of 13C also resulted in diminished body weights, thymic
atrophy, anemia and testicular degeneration (Kelloffet al.,1996).
13C is now marketed as a dietary supplement and has been advocatedas a
chemoproventive agent for women against breastcancer (Wonget al.,1997;
Lawrenceet al.,2000) despite the fact that little is known about the effects of long-
term exposure. The changes that short-term 13C exposure could produce in drug
metabolism and carcinogen activation, along with the previously mentioned
toxicities and evidence indicating that 13Ccan sometimes act as a tumor promoter
(Dashwoodet al.,1991; Oganesianetal.1999; Stoneret al.,2002), raise concerns
as to whether long-term treatment is safe in humans. In this study we use blood
chemistry panels and histopathology of relevant tissues inan attempt to reveal any
potential toxicities in the rat, while also investigating the effect of chronic 13C
exposure on drug and carcinogen metabolizing enzymes.35
Materials and Methods
Chemicals
Indole-3-carbinol was obtained from Sigma-Aldrich Co. (Milwaukee, WI).
Animals
Twenty-seven male Fischer 344 rats were purchased from Simonsens
(Gilroy, CA) at four weeks of age. Ratswere housed individually in hanging metal
wire cages at the Laboratory Animal Resource Center, Oregon State Universityand
maintained at 22°C and 40 to 60 % humidityon a 12 hour light/dark cycle. Both
tap water and powdered semisynthetic diet (AIN-76A)were availablead libitum
throughout the study. After a one week acclimation period, animalswere randomly
divided into 3 different treatment groups, each containing 9 rats (Table 2.1) and 13C
was incorporated into the diet at 0, 1000, or 2500 ppm. At the end of 6 months (5
animals per group) or one year (4 animalsper group) rats were weighed and all
diets were removed overnight before sampling. Ratswere anesthetized and blood
samples were collected as described in the following section. While remaining
under anesthesia, rats were euthanized by exsanguination. Gross pathologywas
performed and a portion of the liver, colon, adrenal, kidneys, testes and prostate
was preserved in neutral buffered formalin for subsequent sectioning and
histopathology. A second portion of the liverwas removed prior to fixation and
immediately frozen in liquid nitrogen and then stored at -80° C until analysis. The36
above protocols were approved by the Oregon State University InstitutionalAnimal
Care and Use Committee.
TABLE 2.1. STUDY DESIGN
Group Duration SupplementDaily DoseRats (N)
1A 6 months - None 5
2A 6 months 13C 1000 ppm 5
3A 6 months 13C 2500 ppm 5
lB 12 months None 4
2B 12 months 13C 1000 ppm 4
3B 12 months 13C 2500 nom 4
Four week old Fischer 344 rats were obtained commercially, acclimated for 1 week and then
randomly assigned to 1 of the 3 treatment groups. The housing, preparation of diet and experimental
details are described in Materials and Methods.
Blood collection and analysis
Blood was collected from the pre-cava while ratswere anesthetized under
4% isoflurane with 02 at a flow of 2 L/min. Bloodwas stored at 4°C for 2 hours
and then spun for 20 minutes at 11,000rpm to isolate serum. An aliquot of serum
was sent to the Texas Veterinary Medical Diagnostic Laboratory (College Station,
TX) where testosterone levelswere determined by a commercial radioimmunoassay
from Diagnostic Products Corporation (Los Angeles, CA) anda small animal37
clinical chemistry analysis was performed utilizinga Hitachi 911 Chemical
Analyzer (Roche, Indianapolis, IN).
Histopathology
Tissues were fixed in 10% neutral buffered formalin and processedon a
LX300 Tissue Processor (Fisher Scientific). Sectionswere cut at 4-5 microns and
stained on the S/P Automatic Slide Stainer GLX with Haematoxylin (Gill-3,
Shandon Inc.-Pittsburgh, PA) and Eosin Y (alcoholic, Shandon Inc.-Pittsburgh,
PA). Slides were coverslipped with Shur/Mount (Triangle Biomedical Sciences-
Durham, NC).
Microsome preparation and total CYP
Liver samples were homogenized with Brinkmann Polytron (Westbury, NY)
into 3 volumes of cold homogenization buffer (10 mM potassium phosphate[pH
7.5] containing 0.15 M potassium chloride, 1 mlvi EDTA, and 0.1 mM
phenylmethylsulfonyifluoride (PMSF)). Microsomeswere prepared by
ultracentrifugation according to Guengerich (1989). Protein levelswere determined
by the method of Lowry et al. (1951). The total liver microsomal CYPcontent was
quantified by the CO versus CO-reduced difference spectra (Omura and Sato, 1964)
on a Cary 300 UV-Vis spectrophotometer (Varian, Walnut Creek, CA).
Electrophoresis and immunoblotting
Microsomal proteins were resolved by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) (Laemmli, 1970) and38
electrophoretically transferred to nitrocellulose membrane (Towbinet al., 1979).
The membranes were incubated with goat antibodies recognizingrat CYP1A1/2
(Oxygene2, Dallas, TX)or CYP3A2 (Gentest, Woburn, MA) and probed with
rabbit anti-goat secondary antibody conjugated with horseradish peroxidase
(Kirkegaard & Perry Laboratories, Gaithersburg, MD). The blotswere visualized by
a chemiluminescence detection kit (New England Nuclear, Boston, MA) and
densitometry was performed usingan HP Scanjet llcx flatbed scanner and NIH
Image software version 1.6 1/ppc (public domain, National Institutes of Health).
2No longer in business.
Statistics
Treatments were compared separately within the 1 year and 6 month data
sets. The three treatments (control, 13C- 1000 and 13C-2500) were compared using
ANOVA followed by pairwise comparisons and linear contrasts whenever data (on
original or log transformed scale)were consistent with assumptions of the methods
(homogenous normal errors). When apparent outlierswere present, non-parametric
rank methods were used (Kruskal-Wallis test followed by Wilcon tests for pairwise
comparisons). When heterogeneous normalerrors were present, a mixed linear
model allowing heterogeneous errors by treatmentwas used (approximate F-tests
followed by approximate t-tests both using the Kenward-Rogers adjustment in the
Mixed Procedure of SAS). Analyses were conducted using SAS version 8.2 (SAS
Institute, Inc., Cary, NC (2001)).39
Results
Body weights
At time of sacrifice there was significant evidence ofa treatment related
reduction in body weight for rats at both 6 (p=O.Ol5) and 12 (p=O.006) months
(Figure 2.1). Differences of 11 and 13 % in weightwere observed between rats
receiving control diet and 2500ppm 13C for 6 and 12 months, respectively.
Figure 2.1: Body weights of rats fed control, 1000ppm 13C or 2500 ppm 13C for 6
or 12 months. *p<0.05 compared to corresponding controlgroup.
Clinical chemistry and testosterone levels
Small animal chemistry panels of rat serum revealed insignificant
differences except for the level of globulin after 6 months ofexposure (Table 2.2),
the levels of calcium and amylase after 12 months (Table 2.3), anda general40
TABLE2.2.CLINICAL CHEMISTRY FOR RATS AFTER 6 MONTHS OF
DIETARY EXPOSURE
Group
IA
2A
3A
Serum
Protein Albumin Calcium PhosphorousGlucose BUN
7.2±.094.9±.13 9.9±.08 5.8±.22 165±30 23.2±1.1
7.2+.104.7+.14 9.9+07 5.6+19 173±7 22.8+0.6
7.3+.144.4±13 10.1+.10 5.2+28 177±1021.3±1.8
Group
IA
LreatinineBilirubin Globulin GGT AmylaseCholesterol
0.124-.02 1.8+0 2.3±.09 <3 2946±47 184±17
2A 0.12±.02 1.8±0 2.6±.05* <3 2726±48 162±8
3A 0.16+.04 1.8+0 2.903* <3 2831+98 221+9
* =p< 0.05 compared to corresponding controlgroup.
TABLE 2.3. CLINICAL CHEMISTRY FOR RATS AFTER 12 MONTHS OF
DIETARY EXPOSURE
Serum
Group Protein Albumin Calcium PhosphorousGlucose BUN
lB 6.1±0 4.0±13 10.7+.21 5.5±40 202±13 38.8-1-8.2
2B 6.1+0 3.7±1810.1i.18* 5.3±.23 184+22 34.7±8.9
3B 6.1±0 3.9±.19 10.1±.09 -±.33 191±9 26.0±5.7
Group CreatinineBilirubin Globulin GGT AmylaseCholesterol
lB .38+101.11±26 2.2±0.1 <3 2683±73271+29
2B .33±.080.78±.32 2.4±.29 <3 2430±323243+47
3B .20+.100.37+.032.3+09 <3 3069+140*210+27
*=p< 0.05 compared to corresponding controlgroup.120
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2: Serum aspartate aminotransferase levels in male Fischer 344 rats after 6
12 (bottom) months dietary 13C exposure. Values represent group
in U/L ± SE. *= p<O.O5 compared to corresponding control group.42
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Figure 2.3: Serum alanine aminotransferase levels in male Fischer 344 rats after 6
(Top) or 12 (Bottom) months dietary 13Cexposure. Values represent group
averages in U/L ± SE. * = p<0.05 compared to corresponding control group.43
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Figure 2.4: Serum alkaline phosphatase levels in male Fischer 344 rats after 6
(Top) or 12 (Bottom) months dietary 13Cexposure. Values represent group
averages in U/L ± SE. * = p<O.05 compared to corresponding control group.UIL
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Figure 2.5: Serum creatine kinase levels in male Fischer 344 rats after 6 (Top)or
12 (Bottom) months dietary 13C exposure. Values representgroup averages in U/L
± SE.*= p<O.O5 compared to corresponding control group.45
decrease in serum enzyme levels at both time points (Figures 2.22.5). At six
months a strong linear trend of increasing globulins with increasing13C dose was
observed (j<O.00Ol) but the trendwas not evident in the 12 month data. After 12
months of exposure, a linear trend of decreasing calcium levels with increasing13C
was observed (p==O.O 149), along with a significant treatment related effect on
amylase levels (p=O.0l 6). As mentioned above, there isa trend of decreasing
serum enzyme levels with an increase in 13C exposure at both 6 and 12 months.
This decrease was significant for alkaline phosphatase (p<O.000l), creatine kinase
(pO. 0003), aspartate aminotransferase (p=O.0062), and alanine aminotransferase
(p=O.Ol7) after 6 months, but for alkaline phosphatase only after 12 months.
Analysis of serum testosterone levels lead to opposite results at 6 and 12 months
(Figure 2.6). After 12 months therewas evidence of an increasing trend with dose
(p=O.O38) and at 6 months an insignificant decreasing trend (pO.O59).
Histopatizology
No significant differences between groupswere noted upon necropsy or
following histopathology at 6 or 12 months. Most notably,no toxicities were
indicated in treatment groups as compared to controls in the liver (Figure 2.7) and
no effects were seen in hormone responsive tissues such as prostate and testes
(Figures 2.8 and 2.9). There werenumerous large hyalirie casts found in the kidney
tubules. The appearances of such castsare common in rats with age (Lord and
Newberue, 1990), and no treatment related differenceswere evident (Figure 2.10).46
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Figure 2.6: Serum testosterone levels in male rats after 6 (top)or 12 (bottom)
months exposure to 13C. Values representgroup averages ± SE. *p <0.05
compared to corresponding control group.47
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Figure 2.7: Photomicrographs of haematoxylin stained liver fromrats fed control
diet (top), diet containing 1000 ppm 13C (middle), and diet containing 2500ppm
13 C (bottom) for 12 months. The preparation of tissueswas as described in the
Materials and Methods. Bar= 50 pm.48
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Figure 2.8: Photomicrographs of haematoxylin stained prostate from rats fed
control diet (top), diet containing 1000ppm 13C (middle), and diet containing 2500
ppm 13C (bottom) for 12 months. The preparation of tissues was as described in
the Materials and Methods. Bar= 50tm.49
- r*
I1*h ._ /4ij:
I 4 Ia'2
... S:
..
-' 1* ,;
>/ 4
*
:?",
; :
,4;
:
i.. e
4
:
4I
'
Figure 2.9: Photomicrographs of haematoxylin stained testes from rats fed control
diet (top), diet containing 1000ppm 13C (middle), and diet containing 2500 ppm
13 C (bottom) for 12 months. The preparation of tissueswas as described in the
Materials and Methods. Bar= 50pm.50
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Figure 2.10: Photomicrographs of haematoxylin stained kidney fromrats fed
control diet (top), diet containing 1000ppm 13C (middle), and diet containing 2500
ppm 13C (bottom) for 12 months. The preparation of tissues was as described in
the Materials and Methods. Bar= 50p.m.51
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Figure 2.11: Total hepatic microsomal CYP levels in rats after 6or 12 months of
dietary 13C exposure. Values represent group averages ± SE.
CYF levels
The total hepatic CYP content of rats after 6 and 12 monthsexposure to 13C
is shown in Figure 2.11. Therewas a strong increasing linear trend in total CYP
with increasing 13C exposure at both time points (p<0.0001, Figure 2.11). 13Cwas
also an effective inducer of CYP1A1/2 and CYP3A2 after both 6 and 12 months of
exposure. Western blots and immunoquantitation of CYP1A1/2 and CYP3A2 are
shown in figures 2.12 and 2.13, respectively. Relative band densities of hepatic
CYP1A1/2 were increased 10- and 31- fold in rats after 6 months of 13Cexposure.
After 12 months CYP 1 Al /2 was not detected in control rats, but induction similar
to the 6 month data was observed in the 13C treated groups. The band densities of
hepatic CYP3A2 were elevated approximately 3- and 6- fold in rats after 6 months
of exposure to 1000 and 2500 ppm 13C, respectively. After 12 months the52
induction of CYP 3A2 was elevated to 5 (1000 ppm)- and 30 (2500 ppm)- fold the
level found in the control group.
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Figure 2.12: Western blots (6 month 13C exposure-top inset, 1 year 13C exposure-
bottom inset) aiid densitometry of male rat liver microsomes for CYP1A1/1A2.
Microsomal protein (22.5 ,.tg) from rat livers was resolved by SDS-PAGE, probed
with antibody to CYP1A1/1A2, and densitometry performed as described in
Materials and Methods section. Lanes 1-3 (6 month) and 1-4 (1 year) represent
microsomes from rats fed control diet. Lanes 4-6 (6 month) and 5-8 (1 year)
represent microsomes from rats exposed to 1000 ppm 13C. Lanes 7-9 (6 month)
and 9-11 (1 year) represent microsomes from rats exposed to 2500 ppm 13C. Lane
10 (4 pmol) (6 month) and lanes 12 (1.3 pmol) and 13 (3 pmol) (1 year) represent
purified CYP1A1 standards.53
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Figure 2.13: Western blots (6 month 13C exposure-top inset, 1year 13C exposure-
bottom inset) and densitometry of male rat liver microsomes for CYP3A2.
Microsomal protein (21tg)from rat livers was resolved by SDS-PAGE, probed
with antibody to CYP3A2, and densitometry performedas described in Materials
and Methods section. Lanes 1-4 (both blots) represent microsomes from rats fed
control diet. Lanes 5-8 (both blots) represent microsomes from rats exposedto
1000 ppm 13C. Lanes 9-12 (6 month) and 9-11 (1 year) represent microsomes from
rats exposed to 2500 ppm 13C. Lanes 13(.5 pmole) and 14 (0.1 pmole) (6 month
blot) and 12 (.1 pmole), 13 (.25 pmole) and 14 (.5 pmole) (1year blot) represent
purified CYP3A2 standards.54
Discussion
The significant evidence ofa treatment related reduction in body weight for
rats receiving 13C in their diet for 6 and 12 months may suggestsome toxicity,
especially at the 2500 ppm dose. When body weights and food consumptionare
considered, 2500 ppm is equivalent to approximately 60 mg/kg. These findingsare
consistent with data from sub-chronic studies showing that weight reduction in
dogs occurred at less than 150 mg/kg (Kelloffet al.,1996) and toxicities in rat
appeared at doses between 20 and 2000 mg/kg. Fora comparison, the daily
recommended human dose for supplementation is about 10 mg/kg (Life
ExtensionsTM).
The indication of possible 13C toxicity inferred from the body weight data
was not confirmed by chemistry panel analysis. Conversely, the significant
reduction in alkaline phosphatase (ALP), alanine aminotrasferase (ALT),aspartate
aminotransferase (AST), and creatine kinase (CK) levels after 6 months, and the
significant reduction in alkaline phosphatase (ALP) levels after 12 months could
indicate possible protective effects. One hypothesized potential mechanism of
action of 13C as a chemopreventive agent relates to the ability of 13Cto function in
vivo as an antioxidant and as an electrophile scavenger (Shertzeret al.,1988; Fong
et al.,1990; Arnaoet al.,1996; Shertzer and Senft, 2000). Therefore, in this study55
continuous dietary exposure to high levels of 13Cmay have been inhibiting age
related oxidative damage to tissues. Previous work (Dunn and LeBlanc, 1994)
demonstrated that some acid condensation products of 13 C lowerserum
LDL/VLDL cholesterol levels in mice by inhibiting acyl-CoA:cholesterol
acyltransferase (ACAT). Treatment with 13 C failed to providea significant
reduction of cholesterol levels in this study. With the exception of unexplained
effects on globulin levels at 6 months, and calcium and amylase levelsat 12
months, no other significant alterations inserum chemistry were evident.
Unpublished data from sub-chronic studies in our lab have shown
decreasing levels of testosterone with increasing 13 Cexposure. In the current study
testosterone levels appeared to follow this trend after six months but the results
were not significant. This trend was reversed after 12 months of exposure when a
significant increase in testosteronewas observed with increasing 13C dose.
Reductions in serum testosterone levels would be consistent with 13C induction of
CYPs active in testosterone catabolism. The increase in testosterone levelsat 12
months may be associated with the induction of CYP 19 (aromatase) observed in
cell cultures treated with DIM (Sanderson et al., 2001). A similar induction of
aromatase in the rat would lead to higher testosterone levels. We haveno
explanation for the impact that age appeared to haveon 13C mediated effects on
testosterone levels.56
The absence of data indicating toxicity in the chemistry panelwas
confirmed by the histopathological examination. Other than the increasein hyaline
casts in the kidney, no lesions were apparent in any of the tissues examined. The
appearance and severity of this kidney pathology increased with age but was not
treatment related.
The induction of total hepatic CYP, and the specific isoforms CYP1A1/2
and CYP3A2, observed in the current study after chronic oral adminstration of 13C,
is mostly consistent with the inductionseen in previous acute or sub-chronic studies
(Bradfield and Bjeldanes, 1987; Bjeldanesetal., 1991; Wortelboeretal., 1992;
Jellincketal., 1993; Stresseretal., 1994; Larsen-Su and Williams, 1996; Manson
etal., 1997; Katchamartetal., 2000). In a previous study, a seven day exposure to
0.2% dietary 13C resulted in a 24-fold induction in CYP1A1 anda 3-fold induction
in CYP1A2. This is comparable to the 30-fold induction of combined CYP1A1/2
observed in this study after a chronic but similar dose of 13C. In thesame seven-
day study, 0.2% dietary 13C resulted ina 4-fold induction in CYP3A whereas the
chronic treatment in this study resulted ina 6- and 30-fold induction after 6 and 12
months, respectively. It appears that the greater than usual induction of CYP
isoforms observed after 12 months of exposure could be attributedmore to an age
related reduction of CYP levels in rodents (Warringtonetal., 2000), rather than to
higher induction. The maximum induction by this dosemay still be reached but the
constitutive level in control rats may be less in older animals. In allcases, the57
degree of induction was similar toor greater than that observed in short-term
feeding studies, indicating that continuousexposure in rats does not result in any
form of "tolerance" as previously demonstrated tooccur in trout (Takahashi et al.,
1995).
Due to the fact that enzyme induction occurs continuously withexposure
there is concern about the long-term effects of 13C supplementation in humans.
The induction of the specific CYP isoforms by 13Cmay play a role in the toxicity
of other compounds. The induction of CYP 1A1 and 1A2 raisesconcerns regarding
the increased activation of polycyclic aromatic hydrocarbons suchas
benzo[a]pyrene and aromatic amines suchas 4-aminobiphenyl. The induction of
CYP 3A may be even more significantas this subfamily contributes to the
metabolism of many clinically relevant drugs (Guengrich, 1999).
In this study direct toxicity of 13C was indicated only bya reduction in body
weight and was not confirmed by chemistry panelsor histopathology. Despite a
possible protective effect against age related tissue damage, the results from this
study confirm our concerns about the potential impact of dietary supplementation
with 13C, with respect to alterations in drug and carcinogen metabolizingenzymes.
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Abstract
Indole-3-carbinol (IC) and 3,' -diindolylmethane (DIM)are naturally
occurring dietary components found in cruciferous vegetables. Inthe stomach, 13C
forms condensation products including DIM. 13C and DIMare marketed as dietary
supplements, but little is known about the safety of long-termexposure. Rats were
fed either control diet, 1- or 1O-X the current human dose of absorption-enhanced
DIM or 5-7-X the maximal recommended dose of 13C. Experimentaldiets were
fed continuously for 3 or 12 monthsor 2 months followed by control diet for 1
month. Results at 3 or 12 monthswere similar in most respects. No significant
differences between groups were found in blood chemistry. A general decreasein
serum enzyme levels in male rats was observed, perhaps indicative of a protective
effect. Males fed 13 C exhibited higherserum levels of 25-hydroxy-vitaminD3
(250H-D3). There were no observable differences grosslyor histologically
between groups, although a high number of hyaline castswere found throughout the
kidneys of all animals. In bothsexes total hepatic CYP levels were significantly
induced by 13C, but not by either dose of DIM. Induction of CYP1A1 and
CYP1A2 in liver and CYP1A1 in colonwas detected for both sexes fed 13C and the
high dose of DIM. CYP3A2was induced in females fed 13C or the high dose of
DIM; males were induced with 13C, but not DIM. No induction ofCYP1B1 in the
colon was observed in either sex. Long-termexposure to DIM produced no
observable toxicity and comparison to 13C indicates that DIM isa markedly less
efficacious inducer of CYP in the rat at doses relevant to human supplementation.Introduction
Indole-3 -carbinol (13 C) and 3,3' -diindolylmethane (DIM)are naturally
occurring plant alkaloids formed by the hydrolysis of indole glucosinolate
(glucobrassicin), found in significant concentrations in cruciferous vegetables such
as broccoli and Brussels sprouts (Bradfield and Bj eldanes, 1987; Slominski and
Campbell, 1987; McDanellet al.,1988; Preobrazhenskayaet al.,1993).
Furthermore, 13C is an unstable compound that undergoes rapid oligomerization in
the acid environment of the stomach to form dimers, trimers, tetramers, and several
other higher order condensation products (Leete and Marion, 1953; Bradfield and
Bjeldanes, 1987; Bjeldaneset al.,1991; Wortelboeret al.,1992). The major
product formedin vitro(Spande, 1979) andin vivoafter oral administration
(Dashwoodet al.,1989; Stresseret al.,1995) is DIM.
Both 13C and DIM are marketedas dietary supplements and are under
investigation as potential chemopreventive agents. 13C requires conversionto these
acid condensation products in order to be chemopreventive againsta wide variety
of carcinogens and is especially effective when administered beforeor during the
initiation phase of carcinogenesis (Bradlowet al.,1999; Shertzer and Senft, 2000;
Murillo and Mehta, 2001). DIM inhibits aflatoxin B1-DNA binding in trout
(Dashwoodet al.,1994) and mammary tumor growth in the rat (Wattenberg and
Loub, 1978; Chenet al.,1998).
Among the hypothesized mechanisms of chemoprevention of 13C and DIM is
their ability to modulate xenobiotic metabolizingenzymes and induce estrogen67
metabolism. When administered through the diet in short-term studies,13C and
DIM induce a number of phase I enzymes in liver and colon, including cytochrome
P450 (CYP) 1A1, CYPIA2, and CYP 3A (Yanget al.,1990; Jellincketal., 1993;
Stresser etal., 1994; Bonnesen etal., 2001; Hornet al., 2002;). Increased activity
of phase I drug-metabolizingenzymes can protect against some carcinogens by
increasing their rate of oxidative metabolism to less toxic metabolites (Park and
Bjeldanes, 1992; Stresser et al., 1994; Xu etal., 1997; He etal., 2000) however,an
increase in activity of certain CYP isozymes could enhance carcinogenicity ofsome
chemicals by increasing their rate of bioactivation (loannides and Parke, 1993).
13C- and DIM- dependent alterations of themonooxygenase systems also raise
concerns relative to their potential adverse effects on druglxenobiotic metabolism.
Studies have shown differential metabolism of tamoxifen and nicotine by liver
microsomes from rats fed 13C (Katchamart et al., 2000). 13C induction of CYPs in
the 1 family markedly enhances estradiol metabolism. CYP1A1 and 1A2 catalyze
the 2-hydroxylation of -estradiol (B2), whereas CYP lB 1 isan effective E2-4-
hydroxylase (Hayes et al., 1996). Both of these metabolitesare catechol estrogens
and represent potential toxic metabolites. Evidence suggests that 4-OH-E2 is the
more reactive and toxic metabolite (Newbold and Liehr, 2000).
Preliminary evidence to date indicates that DIM maybea safer alternative to
13C as it is relatively stable in acid and does not undergo further condensation
reactions, preventing the formations of toxic metabolites suchas indolo[3,2-
b]carbazole (ICZ), a potent aryl hydrocarbon receptor agonist (Bjeldaneset al.,1991) and potential promoter of hepatocarcinogenesis in therat (Herrmannet al.,
2002). DIM induces apoptosis and inhibits growth of humancancer cells (Geet al.,
1996; Chenet al.,2001; Leonget al.,2001; Honget al.,2002) and inhibits
estrogen-dependent mammary tumorigenesis in rats (McDougalet al.,2001).
However, due to poor bioavailability of DIM, itsuse as a supplement has been
limited. The objective of this studywas to evaluate the biological effects of long-
term exposure to rats of an absorbable formulation ofpure DIM, (BioResponse
DIM (Indoiplex )) at the current maximal human dose (US Patent #6,086,915;
Zeligset al.,2002; Andertonet al.,2003). In addition, a pharmacological dose 10
times the current human dose was tested for toxicity and,as a comparison, to a
similar and previously studied dose of 13C.69
Materials and Methods
Chemicals
Jndole-3-carbinol was obtained from Sigma-Aldrich Co. (Milwaukee, WI).
3,3'-Diindolylmethane was provided ina bioavailable formulation (BioResponse-
DIM ) by BioResponse, LLC (Boulder, CO). The DiM contentwas independently
verified by HPLC (Eurofins-Alpha Laboratories, Petaluma, CA).
Animals
One hundred and forty Sprague-Dawley rats (70 each sex)were purchased
from Simonsens (Gilroy, CA) at four weeks ofage. After a one-week acclimation
period, animals were randomly divided into 10 different treatmentgroups, each
containing 7 rats of each sex (Table 3.1). Ratswere housed individually in hanging
metal wire cages at the Laboratory Animal Resource Center, Oregon State
University, and maintained at 22°C and 40 to 60 % humidityon a 12 hour
light/dark cycle. Both tap water and powdered semisynthetic dietwere available ad
libiturnthroughout the study. Groups 1 and 7 received only control (AIN-76A)
diet. The diet for groups 2, 5 and 8was supplemented with I3C to levels providing
a dose of 50 mg/Kg/day. The diets are prepared by thoroughly mixing the indoles
as a powder into the powdered AIN76A diet. The diets were made weekly and
stored at 4°C in sealed containers protected from light. 13C is knownto be
unstable, especially under acidic conditions. Althoughwe did not assay 13C and
DIM in the diets used in this study, a previous study involving long-term feeding of
mice with AIN76A diet demonstrated that under thesesame conditions at least 80%70
TABLE 3-1. STUDY DESIGN
Group Duration SupplementDaily DoseMalesFemales
1 3 months None 7 7
2 3 months 13C 50mg/Kg 7 7
3 3 months DIM 2 mg/Kg 7 7
4 3 months DIM 20 mg/Kg 7 7
5 2 months 13C 50mg/Kg 7 7
1 month - None
6 2 months DIM 20 mg/Kg 7 7
1 month - None
7 12 months - None 7 7
8 12 months 13C 50 mg/Kg 7 7
9 12 months DIM 2 mg/Kg 7 7
10 12 months DIM 20 ma/Ku 7 7
Four week old Sprague-Dawley ratswere obtained commercially, acclimated for 1
week and then randomly assigned to 1 of the 10 treatmentgroups. The housing,
preparation of diet and experimental detailsare described in Materials and
Methods.71
of the 13C was present afterone week (Oganesian et al., 1997). The stability of
DIM is expected to be much greateras we have found it to be relatively stable
under mild acid conditions in air atroom temperature (unpublished observations).
The diets for groups 3, 4, 6, 9 and 10 provided 6.6 mg/Kg/dayor 66 mg/Kg/day
BioResponse DIMTM. On a molar basis, the daily doses of 13C and low and high
DIM were 0.34, 0.008 and 0.08 mmol/Kg, respectively. The approximately2.5 and
25% molar levels of DIM (relative to 13 C)span the range for the percentage of DIM
found after acid condensation reaction of 13Cin vitroorin vivo.
Rats were weighed and food consumption estimated weekly for the first three
months and monthly thereafter. Thegroupswere euthanized after either 3(groups
1-6) or 12 months(groups7-10) of treatment. In order to determine if the effects of
dietary 13C or DIM were reversible, rats ingroups5 and 6 were fed 13C or high
DIM for 2 months and then switched to control AIIN76A diet for 1 month priorto
euthanasia. At the end of the exposure period ratswere weighed and all diets were
removed overnight before sampling. Ratswere anesthetized and blood samples
were collected as described in the following section. While remaining under
anesthesia, rats were euthanized by exsanguination. Gross pathologywas
performed and relevant tissue (see below) weightswere recorded. A portion of the
liver, colon, kidneys, adrenal, uterus and ovaries for females and liver, colon,
kidneys, adrenal, prostate, testicles, and epididymus for maleswas preserved in
neutral buffered formalin for subsequent sectioning and histopathology. A second
portion of the liver and colon were removed prior to fixation and immediately72
frozen in liquid nitrogen and then stored at -80° C until analysis. The carcasses of
rats were stored at 1.5°C for bone density analysis. The above protocols were
approved by the Oregon State University Institutional Animal Care and Use
Committee.
Blood collection and analysis
Blood was collected from the abdominal aorta while rats were anesthetized
under 4% isoflurane with02at a flow of 2 L/min. Blood was stored at 4°C for 2
hours and then spun for 20 minutes at 11,000 rpm to isolate serum. One aliquot of
serum was sent to the Texas Veterinary Medical Diagnostic Laboratory (College
Station, TX) where a small animal clinical chemistry analysis was performed
utilizing a Hitachi 911 Chemical Analyzer (Roche, Indianapolis, IN). A second
aliquot was sent to the Animal Health Diagnostic Laboratory (Lansing, MI) where
circulating 25-hydroxyvitaminD3 (25-OH-D3)levels were determined using a
commercial radioimmunoassay from DiaSorin (Stillwater, MN) and testosterone
levels were determined (males only) using a commercial radioimmunoassay from
Diagnostic Products Corporation (Los Angeles, CA).
Bone density analysis
Three carcasses of each sex, from groups 1, 2, and 4 were sent on ice to
University Colorado Health Science Center (William. E Huffer, M.D., Denver,
CO). The animals were equilibrated to 4° C and the proximal knee joint with
approximately one half of the distal femur and proximal tibia were removed and
fixed for 24 hours in absolute methanol also at 4°C. The specimens were then73
embedded in glycol methacrylate, and sectionedon a rotary microtome with a D-
profile carbon-tungsten steel knife at 5pm. The sections were stained by the von
Kossa technique (Bills et al., 1971) witha hematoxylin and eosin counter-stain to
demonstrate general histology and calcified bone and osteoid, and fortartrate
resistant acid phosphatase to demonstrate osteoclastson bone surfaces.
Measurements of the total and cancellous boneareas, cortical bone thickness, and
the number of osteoclasts in a single section of the tibial metaphysiswere made by
semi-automated histomorphometric methods (Huffer and Lepoff, 1992; Hufferet
al., 1994).
Histopathology
Tissues were fixed in 10% neutral buffered formalin and processedon a
LX300 Tissue Processor (Fisher Scientific). Sectionswere cut at 4-5 microns and
stained on the S/P Automatic Slide Stainer GLX with Haematoxylin (Gill-3,
Shandon Inc.-Pittsburgh, PA) and Eosin Y (alcoholic, Shandon Jnc.-Pittsburgh,
PA). Slides were coverslipped with Shur/Mount (Triangle Biomedical Sciences-
Durham, NC).
Microsome preparation and total CYP
Liver samples were homogenized with a Brinkmann Polytron (Westbury,
NY) into 3 volumes of cold homogenization buffer (10 mM potassium phosphate
[pH 7.5] containing 0.15 M potassium chloride, 1 mM EDTA, and 0.1 mlvi
phenylmethylsulfonylfluoride (PMSF)). Microsomes were prepared by
ultracentrifugation according to Guengerich (1989) and protein levelswere74
determined by the method of Lowryetal. (1951). The total liver microsomal CYP
content was quantified by the CO versus CO-reduced difference spectra (Omura
and Sato, 1964) on a Cary 300 TJV-Vis spectrophotometer (Varian, WalnutCreek,
CA).
Colon lysate preparation
Colons were rinsed with phosphate buffered saline (PBS) toremove mucus
and then scraped with the back ofa scalpel blade to remove cells. Cells were lysed
in a modified RIPA buffer (lx PBS, 1.0% Igepal CA-630, 0.5% sodium
deoxycholate, and 0.1% sodium dodecyl sulfate (SDS) with 1 tablet of Complete-
Mini protease inhibitor cocktail (Roche, Indianapolis, IN) added forevery 10 ml of
buffer) and then sheared by passing througha 23 gauge needle. Sheared cells were
incubated 45 mm on ice after the addition of 0.574 mM PMSF (1:100 froman
isopropanol stock) and then spun at 10,000 rpm for 10 mm at 4°C. Thesupernatant
was removed, protein concentration determined by the method of Lowryet al.
(1951) and stored at -80°C until analysis.
Electrophoresis and immunoblotting
Microsomal and lysate proteins were resolved by SDS-polyacrylamide gel
electrophoresis (SDS-PAGE) (Laemmli, 1970) and electrophoretically transferred
to nitrocellulose membrane (Towbinetal., 1979). The membranes were incubated
with goat antibodies recognizing both rat CYP1A1 and CYP1A2or CYP3A2
(Gentest, Woburn, MA) and probed with rabbit anti-goat secondary antibody
conjugated with horseradish peroxidase (Kirkegaard & Perry Laboratories,75
Gaithersburg, MD) or rabbit antibody raised against rat CYP1B1 (Gentest,Woburn,
MA) and probed with goat anti-rabbit secondary antibody alsoconjugated to
horseradish peroxidase (Gentest, Wobum, MA). The blotswere visualized by a
chemiluminescence detection kit (New England Nuclear, Boston, MA) and
densitometry was perfonned usingan HP Scanjet Jlcx flatbed scanner and NIH
Image software version 1 .61/ppc (public domain, National Institutes of Health).
Statistical analysis
Males and females were analyzed separately. When assumptionswere
reasonably satisfied, treatments were compared usingone-way ANOVA and all
pairwise comparisons with Tukey's multiple comparison adjustment. When
outliers or other non-normality were indicated, simple transformations, suchas
logarithmic, were examined. When the problemwas non-transformable, non-
parametric rank tests (Kruskal-Wallis)were used. In that case pairwise
comparisons were adjusted for multiple comparisons using the global permutation
distribution, after first determining that therewere no problems with extreme
heteroscedasticity or badly unbalanced sample sizes (Westfall et al., 1999). When
preliminary analysis indicated normality but heterogeneity of variance,a general
mixed model allowing heterogeneity of variancewas fit by residual maximum
likelihood (REML) with Tukey adjusted pairwise comparisons. The denominator
degrees of freedom for testing were adjusted by the method of Kenward and Rogers
(SAS, 1999). Statistical analyseswere conducted using SAS version 8.2 (Cary,76
NC). Within SAS/STAT the GLM, Mixed, Nparlway and Muittestprocedures
were used.77
Results
Body and tissue weights
There were no significant differences in diet consumptionor weight gain
between groups. The body weights in bothsexes tended to be lower in the 13 C-fed
group, but the analysis of weights at the time of sacrifice revealed no significant
differences between treatments (p=O.23 and 0.44, ANOVA, for males andfemales,
respectively, Figure 3.1). There were alsono treatment related effects on raw tissue
weights in either sex, although 13 C, but not DIM significantly increased the liver
somatic index (LSI) in males at both the 3 and 12 month time points (Table 3.2).In
the group fed 13C for 2 months followed by control diet for 1 month, theLSI was
lower relative to the group fed 13C for 3 months, but the differencewas not
statistically significant. Both sexes fed 13C had increased LSI after 12 months
relative to controls, but only the increase in maleswas large enough to be
statistically significant after multiple comparison adjustment (p=0.0023t-test,
(Table 3.2) and p=O.086 Wilcoxon for males and females, respectivly). The high
dose of DIM marginally induced LSI in males after 12 months (p=O.042, Tukey-
adjusted t-test), but not in females.
Clinical chemistry,250H-D3and testosterone levels
The results of the clinical chemistry panel with female rats did not demonstrate
any treatment related effects after 3 or 12 months of exposure, with the exception
of phosphorus in females fed the high DIM diet (3.17 mg!dl comparedto 4.20 in
controls, adjusted p value=0.0279, Table 3.3). In males, neither 13Cnor DIM700
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Figure 3.1: Body weights of male (top) and female (bottom) rats fed control, 13Cor
DIM for 12 months.79
TABLE 3.2. LIVER SOMATIC INDEX AT 3 AND 12 MONTHS
Group Treatment LSI (±SD)
1 3monthcontrol 3.58±0.25
2 3monthl3C 4.00±0.45*
3 3 month lowDIM 3.58±0.15
4 3 month highDIM 3.66±0.25
5 2 month 13C/1 month control 3.74±0.26
6 2 monthDIM/imonth control 3.65±0.26
7 l2monthcontrol 2.51±0.18
8 12 month 13C 2.93±0.08*
9 12 month low DIM 2.65±0.23
10 12 month high DIM 2.82±0.24*
LSI= Liver weight/body weightx 100. The results are the mean (±SD).
* Indicates statisticalsignificance at p<O.OS
elevated biomarkers of tissue damage, and in facta general decrease in the levels of
serum enzymes after 12 months of experimental diet administration was observed
in male rats (Figure 3.2). Serum aspartate aminotransferase (AST) levelswere
significantly lower in male rats fed 13Cor either dose ofDIMfor 12 months
(ç<0.013, for each Tukey-adjusted comparison). A heterogeneousvariance mixed
model was used for analysis because rats in the controlgroup exhibited greater
variation than the other groups. Although alanine aminotransferase (ALT) levelsat
12 months were also lower in thesesame rats, the difference, relative to controls,
was not found to be statistically significant due to high variability in the control
group (p>O.1 1, all adjusted pairwise comparisons). Alkaline phosphatase (ALP)
serum levels were reduced in male rats fed 13C (p=O.Ol 0) and the high dose80
TABLE 3.3. CLINICAL CHEMISTRY FOR FEMALE RATS
Group
Serum
ProteinAlbuminCalciumPhosphorousGlucose BUN
I 5.9+.163.8±.21 10.2+.18 5.0+.26 202+9.1 19+.9
2 6.0-'-.lO4.l±.17 10.1+25 4.8±.42 207±11.4 20±1.4
3 5.8±10 4.1±.07 10.1±12 5.2+.40 194±2.7 19±1.2
4 5.7±.08 4.1±.04 10.0±.06 5.1+.25 195±8.8 19±.6
5 5.8±.11 4.0+.11 1O.O+.064.423 2006.9 20±1.0
6 5.9+.11 4.0+.13 9.9+.09 4.8+31 193+7.3 19±.8
7 5.6±.30 3.9-1-.2411.0±23 4.2±.23 189±9.8 19±.9
8 5.3±.30 3.8-'-.19 1O.6±.16 4.O+.18 179±3.9 20±.9
9 5.4±.273.5±.2510.5±.19 3.5±.25 202±10.0 17±.7
106.2±064.4±.0711.3±.12 3.2±.28* 171±9.3 19±1.0
Group CreatinineBilirubinGlobulin GGT AmylaseCholesterol
I 0.14±02 0.1±0 2.1±32 <3 1450±88 101±5
2 0.17±.03 0.1±.01 1.9±.10 <3 1673±142 114±3
3 0.17±.02 0.1±0 1.8±.06 <3 1811+284 109±4
4 0.13+02 0.1±.01 1.6-1-05 <3 1334±38 102±4
5 0.17±.030.1±01 1.8±.09 <3 1685±121 111±5
6 0.14±.02 0.1±0 2.0±.18 <3 1479±66 101±2
7 0.2±.03 0.2±.01 1.7±.06 <3 1212±133 152±15
8 0.17±02 0.2±.01 1.6±12 <3 1019±89 148±10
90.24±.03 0.2±0 1.9±.28 <3 1111±110 129±8
100.22±.020.2±.02 1.8±.06 <3 1216+49 147±5
*=P<0.05
of DIM (p=O.004). The only significant reduction in creatinine kinase (CK)was in
the male rats fed the high dose of DIM (p=O.OlO). At 12 months therewere no
significant differences between control and treatmentgroups in either sex for any of
the remaining serum chemistry measurements (total protein, albumin, calcium,
glucose, BUN, globulins, GGT, cholesterol, amylase, bilirubin, creatinine)(Table
3.3 and 3.4).81
TABLE 3.4. CLINICAL CHEMISTRY FOR MALE RATS
Group
Serum
Protein Albumin CalciumPhosphorousGlucose BUN
I 5.9±10 3.8±.09 1O.0±.12 6.1±.26 194±10 21±1.2
2 5.9+.08 3.9±.05 9.8+.15 6.4+22 194+4 18±.6
3 5.9±.04 3.8+.0310.2+08 6.5±.27 199±8 16+1.4
4 5.8+.06 3.9+07 1O.1±.22 6.8±.16 189±11 19±0.8
5 5.8±.10 3.7±.06 10.1±.12 6.5±.18 202±14 18+1.5
6 5.7-i-.11 3.8±.06 9.8+.15 6.5±.28 203±12 19±1.0
7 6.1.11 3.4+.1211.4+19 4.5±.29 199±31 26±7.8
8 5.8+.29 3.5+.20 11.3±.44 4.1±.29 206±21 17±0.8
9 5.9±.09 3.4±.08 11.7±.17 4.2±21 195±14 24±4.1
10 5.5±.30 3.2±.19 11.5±.24 4.1±.31 198±14 29±7.4
GroupCreatinine Bilirubin Globulin GGT Amylase Cholesterol
I 0.12±.02 0.1±0 2.0±04 <3 2565±132 96±4
2 0.12+.01 0.1±0 2.1±.04 <3 2736±121 116±5
3 0.12±.01 0.1±0 2.1±.04 <3 2641±70 103±5
4 0.10±0 0.2±02 1.9±05 <3 2745±126 110±6
5 0.14+.02 0.1±.01 2.1±.12 <3 2665±163 108±6
6 0.10±0 0.1+0 2.0±.05 <3 2508±89 101±4
7 0.49+.160.2+03 2.7±.12 <3 2233±79 239±29
8 0.17±03 0.1+.02 2.3±14 <3 2392±138 274±25
9 0.34±.06 0.1+.01 2.5±.14 <3 2720±163 288±32
10 0.42+.17 0.1+.02 2.3+.14 <3 2747±234315±24
Serum 25-OH-D3 levels were increased(p=O.037land0.003 1for males and
females, respectively) about 50% by dietary13Cin both sexes after 12 months. At
3months only the males exhibited elevatedserum levels of 25-OH-D3. Again, the
13Cdiet increased levels by about 50%. The high dose of DIM also appeared to
increase 25-OH-D3 in serum, but the changewas not significant (data not shown).82
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Figure 3.2: Serum enzyme levels in males after 12 monthsexposure to 13C or
Dilvi. AST and ALT (Top); ALP and CK (Bottom). Values representgroup
averages in U/L ± SE. *p<O.O5.83
Serum testosterone levels in males were not altered by test diets.E2levels were
unchanged by 13C or DIM at both the 3 and 12 month time points (data not shown).
Histopathology
No significant differences between groups of either sex at 12 months were
noted upon necropsy or following histopathology. Most notably, no effects were
seen in hormone responsive tissues such as prostate in male rats (Figure 3.3) and
ovaries in female rats (Figure 3.4), and no toxicities were indicated in treatment
groups as compared to controls in the liver (Figures 3.5 and 3.6). There were
numerous, large hyaline casts found in the kidney tubules. The appearance of such
casts is common in rats as they age (Lord and Newberue, 1990), and no treatment
related differences were evident (Figures 3.7 and 3.8).
CYP levels
The total hepatic CYP of the male and female rats at 12 months is shown in
Figure 3.9. A significant increase in total CYP was observed in the 13C
supplemented groups of both sexes. DIM did not significantly induce total hepatic
CYP in either sex.
As previously demonstrated by our laboratory and others (Bradfield and
Bjeldanes, 1987; Bjeldaneset al.,1991; Wortelboeret al.,1992; Stresseret al.,
1994; Larsen-Su and Williams, 1996; Mansonet al.,1997; Katchamartet al.,2000)
13C effectively induces CYP1A1 and 1A2 levels in liver microsomes following oral
administration. After 3 months, CYP1A1/1A2 was induced 20- and 44-fold in rat
liver microsomes from males and females, respectively. DIM also significantly84
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Figure 3.3: Photomicrographs of haematoxylin stained prostate from control(top),
13C (middle), and DIM (bottom) treated rats at 12 month time point. The
preparation of tissues was as described in the Materials and Methods. Bar 50pm.85
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Figure 3.4: Photomicrographs of haematoxylin stainedovary from control (top),
13C (middle), and DIM (bottom) treated rats at 12 month time point. The
preparation of tissues was as described in the Materials and Methods. Bar= 50tm.86
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Figure 3.5: Photomicrographs of haematoxylin stained liver from control (top),
13C (middle), and DIM (bottom) treated male rats at 12 month time point. The
preparation of tissues was as described in the Materials and Methods. Bar= 50p.m.87
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Figure3.6:Photomicrographsofhaematoxylin stained liver from control (top),
13C(middle), andDIM(bottom) treated female rats at12month time point. The
preparationoftissues was as describedin the Materials and Methods. Bar=50tm.88
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Figure 3.7: Photomicrographs of haematoxylin stained kidney from control(top),
13 C (middle), and DIM (bottom) treated male rats at 12 month time point.The
preparation of tissues was as described in the Materials and Methods. Bar=50 p.m.89
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Figure 3.8: Photomicrographs of haematoxylin stained kidney from control (top),
13C (middle), and DIM (bottom) treated female rats at 12 month time point. The
preparation of tissues was as described in the Materials and Methods. Bar= 50tm.90
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Figure 3.9: Total hepatic microsomal CYP levels in male and female rats after 12
months of dietary exposure. The bars representgroup averages ± SE. * = p<O.OS.
induced CYP1A1/1A2 but to a much lesser degree (2- and 10-fold for males and
females, respectively, data not shown). Immunoquantitation of CYPIAI and
CYP 1 A2 in liver of rats at 12 months is shown in figure 3.10 (males) and figure
3.11 (females). Relative band densities of hepatic CYP1A1were increased 82
(p<O.001)- and 16 (p=0.032)-fold in male rats fed diets containing 13Cor the high
dose of DIM, respectively. CYP1A1was not detected in the livers of control
female rats but band densities were induced to levels 9-fold higher in 13C1234567891011121314
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Figure 3.10: Western blot (inset) and densitometry of CYP 1A1 and 1A2 in liver
micromsomes from male rats administered control diet, 13Cor the high dose of
DIM for 12 months. Microsomal proteins (24 jig) from rat liverswere resolved by
SDS-PAGE, transferred to nitrocellulose membranes and probed witha goat
antibody that recognizes both rat CYP 1A1 and 1A2. Lanes 1-3were controls;
lanes 4-7 rats fed 13C; lanes 8-11 rats fed the high dose of DIM; lanes 12-14were
CYP1A1 standards (0.5, 1.0 and 2.0 pmol).
supplemented animals than in the DIM treatedgroup. The band densities of hepatic
CYP1A2 were elevated approximately 40-fold(p<O.001) in both male and female
rats given 13C but only 10-fold in rats fed diet containing the high dose of DIM. In
the colon, CYP1A1 band densitieswere induced 10- and 8-fold (males) and 8- and
3-fold (females) in the 13C and DIMgroups, respectively (Figure 3.12). No
evidence was seen for CYP 1 B 1 induction in the colon of eithersex following1234 567891011 12 1314
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Figure 3.11: Western blot (inset) and densitometry of CYP 1 Al and 1 A2 in liver
micromsomes from female rats administered control diet, 13C or the high dose of
DIM for 12 months. Microsomal proteins (24 tg) from rat livers were resolved by
SDS-PAGE, transferred to nitrocellulose membranes and probed with a goat
antibody that recognizes both rat CYP 1A1 and lA2. Lanes 1-3 were controls;
lanes 4-7 rats fed 13C; lanes 8-11 rats fed the high dose of DIM; lanes 12-14 were
CYP1A1 standards(0.5, 1.0and 2.0 pmol).
administration of 13C or DIM for 12 months (data not shown). After 12 months, in
females exposed to 13C, CYP3A2 band densities were increased5-and 2-fold with
13C and DIM, respectively (Figure 3.13). 13C induced the CYP 3A2 band density
almost 2-fold in male rats but no induction was observed with DIM exposure.1234 5678 910111213
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Figure 3.12: Western blot (inset) and densitometry of CYP1A1 in colonic lysates
from male and female rats administered control diet, 13Cor the high dose of DIM
for 12 months. Lysate proteins (80 gig) from rat colonwere resolved by SDS-Page,
blotted onto nitrocellulose and probed with goat antibodyto rat CYP1A1 as
described in Materials and Methods. Lanes 1-3are from rats fed control diet; lanes
4-7 from rats fed 13C; lanes 8-10 (male, top inset) and 8-11 (female, bottom inset)
from rats fed the high dose of DIM and lanes 11-13 (top inset)or 12-14 (bottom
inset) were 1.0, 0.5 and 0.25 pmol, respectively of CYP1A1 standard.
Bone density
Qualitative and histomorphometric analysis of methacrylate-embedded
undecalcified cancellous and cortical bone from mature Sprague-Dawleyrats
showed that, in comparison to the controlgroup, the 13C and DIM diets were not
associated with any additional adverse effectson bone density, structure, or
turnover. All three groups had cancellous osteoporosis moresevere than that-
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Figure 3.13: Western blot (inset) and densitometry of CYP3A2 in liver
microsomes from male (top inset) and female (bottom inset) rats administered
control diet, 13C or the high dose of DIM for 12 months. Microsomal proteins (24
g) were resolved by SDS-PAGE, blotting onto nitrocellulose and probed withgoat
antibody to rat CYP3A2 as described in Materials and Methods. Lanes 1-3 (male)
and 1-2 (female) are from rats fed control diet; lanes 4-7 (male) and 3-7 (female)
are from rats fed 13C diet; lanes 8-11 are from rats fed the high dose of DIM; and
lanes 12-14 are 1.0, 0.5 and 0.25 pmol, respectively of purified CYP3A2.
observed in control rats from previous studies where other dietswere utilized. This
osteoporosis was more severe in male than female rats (data not shown).95
Discussion
The doses tested in the studywere based on the current maximal human dose of
DIM of 2 mg/Kg which was provided bya daily dose of 6.6 mg/Kg formula weight
of BioResponse-DIM® (Indoloplex®). Twenty mg/Kg DIMwas provided by a daily
dose of 66 mg/Kg BioResponse-DIMTM to givean exposure 10 times higher than
the current human dose, to amplifyany potential toxicity not apparent at the lower
dose. The 13C exposure utilized (50 mg/kg/day)a dose shown in previous studies
to result in levels of DIM in human blood complimentary to the level observed
when exposed to 66 mg/Kg/day BioResponse-DIM® (Arnesonet al.,2001; Zeligs
et al.,2002) and that represents approximately 5-7 times the daily dose
recommended by commercial suppliers of 13C supplements.
The body weights and organ weights did not suggestany chronic treatment-
related toxicity with the possible exception of liver. A previous study showed that
after a 15 day treatment of 0.5% 13 C in the diet of rats, the liver somatic indexwas
significantly increased from 4.4% in controls to 6.4% (Mansonet al.,1997). The
smaller but chronic doses of 13C and DIM in this study also resulted ina significant
increase in the LSI. A 3 month oral administration of 13C to rats at doses of 4, 20
or 100 mg/Kg/day also demonstrated an increased LSI (at the 20 and 100
mg/Kg/day doses). In that same study, histopathological changes in liverwere
observed at the 100 mg/Kg/day doseas well as a decrease in testes weights at all
doses (Nd, 1996). These differencesmay be related to the method of
administration (diet versus gavage). This increase in LSI observed inour study96
with 13 C or DIM correlates with the degree of CYP induction thatwas also
observed, as 13C was a more efficacious inducer of CYP and also hada greater
effect on LSI when compared to DIM. 13C significantly enhanced LSIin males
after 3 or 12 months. The high dose of DIM also increased LSI but onlyafter 12
months. The increase was notas marked as with 13C and was seen only in males.
We have no explanation for the effect ofsex on LSI.
Clinical chemistry panels failed touncover any significant differences between
control, 13C, and DIM treated rats that would indicate toxicity. Conversely,the
significant reduction in creatine kinase (CK) in male rats fed DIM, and the
significant reduction in alkaline phosphatase (ALP) andasp artate aminotransferase
(AST) in rats fed 13C or DIM could indicate possible protective effects againstage
related tissue damage. This may be explained by the antioxidant and electrophilic
scavenging properties described for 13C and DIM (Arnaoet al.,1996; Fonget al.,
1990; Shertzeret al.,1988; Shertzer and Senft, 2000). Again, this significant
reduction in the serum enzyme markerswere only evident in male rats after 12
months of dietary exposures. Withone exception, no other significant alterations in
serum chemistry following 12 months of exposure to 13C or DIM was evident. In
previous work some acid condensation products of 13Cwere shown to lower serum
LDL/VLDL cholesterol levels in mice (Dunn and LeBlanc, 1994), resulting from
the inhibition of acyl-CoA:cholesterol acyltransferase (ACAT). Treatment with
13C or DIM failed to provide cholesterol lowering effects in this study. The dietary
indoles did not alter serum levels of testosterone in malesorE2in females. The97
fact that there were no significant changes in testosterone levels in this studymay
not be surprising considering the individual variation normally observed in
testosterone levels in rats (Overpecket al.,1978) and that 750 mg/kg of 13C were
needed to cause a significant effect in shorter-term studies (Wilsonet al., 1999).
Clinical trials with 13C have documented reductions in urinary E2 levels in both
men and women concurrent with an increase in the 2-OH-E2/16c-OH-E2 ratio
(Michnoviczetal., 1997) and absorption-enhanced DIM also increased this ratio in
a pilot clinical study (Zeligsetal., 2002).
The basis for investigation of both the25-OH-D3levels and bone density stem
from reports of individuals with low25-OH-D3and a decrease in bone density
while on 13C. The concern regarding vitaminD3is that enzyme induction in the
colon or liver could influence levels of this vitaminlhormone which inturn could
affect bone density. It has also been shown that bone densitycan be influenced by
estrogen metabolism, especially CYP 1 A-dependent 2-hydroxylation (Leelawattana
et al., 2000). There appears to be greater bone density with lower ratios of 2-OH/
1 6a-OH estrogen levels in postmenopausalwomen, implying that increasing this
ratio with 13C or DIM could result in lower bone density. No effecton bone
density was observed in this study following 13Cor DIM exposure. DIM had no
significant effects on25-OH-D3levels, however significant increases were
observed in males fed 13C for 3 or 12 months and in females fed 13C for 12 months.
The absence of data indicating toxicity in the chemistry panel and other blood
work was confirmed by the histopathological examination. Other than the increasein hyaline casts in the kidney,no apparent lesions were observed in any of the
tissues examined. The appearance and severity of this kidney pathologyincreased
with age but was not treatment related.
The induction of CYP isoforms observed in this study is mostlyconsistent with
data from previous acute or sub-chronic studies. The 24-, 3-, and 4- fold induction
of CYPs 1A1, 1A2, and 3A1/2, respectively, in male Fischer 344rats consuming
0.2% 13C in their diet for seven days (Stresser et al. 1994)can be compared to the
82-, 40-, and 2- fold inductions observed in male Sprague-Dawley rats in this study
after administration of a similar dose of 13 Cover a much longer time.
Whereas direct toxicity by long-termexposure to 13C and DIM is not evident in
this study, the induction of CYPs, especially those of the 1 A subfamily,could be a
cause for concern, given the role of these enzymes in activation of polycyclic
aromatic hydrocarbons such as benzo[a]pyrene and aromatic amines suchas 4-
aminobiphenyl or PhIP. The induction of CYP 3Amay also be significant as this
subfamily contributes to the metabolism of 50-60% of all clinically relevant drugs
(Guengrich, 1999). The dampened induction of CYPsseen with DIM exposure
may result in fewer drug interactions with DIM supplementation, when compared
to 13C. When all endpoints in this study are considered in the comparison between
13 C and DIM, the differences can be contributed toa magnified effect in the
increased liver somatic index, total CYP, and induction of specific CYPs in the 13C
treated group. The higher efficacy/potency of 13C is expected and relatedto the
fact that in the acidic conditions of the stomach after oralexposure, 13 C becomes acomplex mixture of not only DIM butmore than 20 different 13C-derived
compounds, all having pharmacological/toxicological effects, suchas possessing
different affinities for the Ah receptor. One of these compounds, ICZ, bindsto the
Ah receptor with an affinity similar to 2,3,7,8-tetrachlorodibenzo-p-dioxin(TCDD).
DIM has been shown to be relativelymore stable in acid and does not robustly
undergo further condensation reactions.
The data from this study confirm results from short-term studies indicating that
both 13C and DIM are relatively non-toxic compounds. Furthermore, these results
confirm earlier long-term feeding studies in other models, including therainbow
trout and the same strain of rat used in the present study, that 13C is nota complete
carcinogen (Dashwoodetal., 1991; Oganesianetal., 1999; Stoneretal., 2002). A
concern, however, with the prolonged use of 13C for cancer chemoprevention is its
potential for promotion of liver neoplasms. 13C isan effective promoter of liver
cancer in the trout (Dashwoodetal., 1991; Oganesianetal., 1999) and recent
studies in a multi-organ model (female Sprague-Dawleyrats initiated with 7,12-
dimethylbenz[a]anthracene for breast, aflatoxinB1for liver and azoxymethane for
colon) demonstrate that long-term post-initiation with dietary 13C could provide
some chemoprotection in breast and colon, but not without a significantly increased
risk for liver neoplasms (Stoneretal., 2002). The long-term post-initiation effects
of 13C in hepatocarcinogenesis are not consistentacross species as this treatment
with C57 black mice, initiated at 15 days ofage with diethylnitrosamine, provided
significant protection (Oganesianetal., 1997). The mechanism(s) of 13C tumor100
modulation need to be established in these models in order toassess the risk to
human health.
Previous work from our laboratory utilizing the rainbow trout has shown both
13C and DIM to be estrogenic (Shilling & Williams, 2000; Shillinget al.,2001).
The estrogenicity of 13C is a likely mechanism by which 13Cpromotes
hepatocarcinogenesis in trout (Oganesianet al.,1999). We have not yet tested DIM
in trout as a tumor promoter. DIM is primarilyan anti-estrogen in mammalian
systems (Chenet al.,1998; McDougaletal., 2001). We hypothesize that this
difference may be a function of species-specific DIM metabolism. We have
preliminary evidence that CYP-dependent hydroxylation of DIM is required introut
to elicit estrogenicity (Shillingetal., 2001).
Also confirmed were the alterations observed in themonooxygenase system
that could be important in carcinogen bioactivaionldetoxication and potential
adverse effects on drug metabolism. The results from this studysuggest that DIM
is a markedly less efficacious inducer of CYP in the rat but further studiesare
required to investigate the effects of both 13C and DIMon carcinogenesis,
metabolism, and human health.101
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Abstract
Indole-3-carbinol (13C) and 3,3 '-diindolylmethane (Dll\'I)are naturally
occurring dietary components found in cruciferous vegetables. Theyare now
marketed as dietary supplements andare under investigation as chemopreventive
agents, despite limited data on the effects of chronicexposure. Among the
concerns for chronic exposure is the well documented potential for phytochemicals
to trigger drug interactions through modulation ofenzyme levels and activities.
This concern is relevant in thecase of 13C and Dilvi, as it has been demonstrated
that short-term exposures of rats to 13C arid DIMare capable of altering
monooxygenase levels. 13C and DIM repress expression of flavin-containing
monooxygenase (FMO) 1 in liver and intestine of rat with concurrent induction of
several isozymes of cytochrome P450 (CYP). FMO and CYP have overlapping
substrate specificities, but usually yield different products. 13C and DIMcan
thereby alter the metabolic profile of drugs and xenobiotics. Thecurrent study
utilizes the high precision liver slice model to investigate the potential for chronic
exposures to 13C and DIM to alter drug metabolism. Rats were fed either control
diet, 5-7-X the maximal recommended dose of 13Cor 10-X the current human dose
of absorption-enhanced DIM for 12 months. Sliceswere prepared from liver and
incubated with '4C- N,N-dimethylaniline (DMA) for 30 minutes. DMA isa
substrate for both FMO (N-oxygenation) and CYP (N-demethylation). A high
performance liquid chromatography (HPLC)assay was employed to quantitate14C-111
DMA metabolites. Incubations of '4C- DMA with slices from controlrats resulted
in approximately 90% of the total metabolites formedas the result of FMO
mediated N-oxygenation and approximately 10 % the result of N-demethylationby
CYP. The percentage of metabolites formed from each pathwaywas around 50%
in rats treated with 13C. The metabolic contribution of FMO andCYP in
incubations with slices from DIM treated ratswas 80% and 20%, respectively. The
modulation of DMA metabolism observed in this study confirmsour concern that
chronic 13C and DIM exposuremay result in significant alterations to the efficacy
and toxicity of drugs andlor xenobiotics. Further studies should beperformed to
determine the potential for a similarresponse in humans.
Abbreviations: 13 C, indole-3-carbinol; DIM, 3,3' -diindolylmethane; DMA, N,N-
dimethylaniline; CYP, cytochrome P450; FMO, flavin-containingmonooxygenase;
ACPs, acid-condensation products.112
Introduction
Indole-3-carbinol (13C) is a naturally occurring plant alkaloid formed by the
hydrolysis of indole glucosinolate (glucobrassicin), found in significant
concentration in cruciferous vegetables suchas broccoli and Brussels sprouts
(Bradfield and Bjeldanes, 1987; Slominski and Campbell, 1987; McDanellet al.,
1988; Preobrazhenskaya et al., 1993). Furthermore, 13C isan unstable compound
that undergoes rapid oligomerization in the acid environment of thestomach to
form dimers, trimers, tetramers and several other higher order condensation
products (Leete and Marion, 1953; Bjeldanes etal., 1991; Wortelboeret al., 1992).
The major product formed in vitro (Spande, 1979) and in vivo after oral
administration (Dashwood et al., 1989; Stresser et al., 1995) is 3,3-
diindolylmethane (DIM).
Both 13C and DIM are marketed as dietary supplements andare under
investigation as potential chemopreventive agents, despite the fact that little is
known about the effects of chronicexposure. One area of concern for chronic
exposure to such phytochemicals is the well documented occurrence of drug-drug
interactions as a result of phytochemical induced modulation of metabolizing
enzymes. The most prominent example involves alteration of blood levels of drugs
in patients consuming grapefruit juice (Bailey etal., 1994). In thiscase
furanocoumarins in the grapefruit juice actas mechanism based inhibitors and113
inhibit the expression and activity of CYP3A4, a CYP isoform responsible for the
metabolism of 50-60% of all therapeutic drugs (Guengrich, 1999). This results in
an improved bioavailability of drugs such as midazolam, cyclosporine, and
felodipine leading to an increase in efficacy or enhanced toxicity depending on the
therapeutic index.
The concerns over potential drug-drug or food-drug interactions as a
consequence of 13 C and DIM exposure are substantiated by data from previous
studies demonstrating similar enzyme interactions. The induction of numerous
CYP isoforms resulting from dietary exposure of 13C and DIM in rats has been well
documented. Short term 13C exposure produced 2-4 fold inductions of CYP1A2,
CYP2B1I2, and CYP3A with over 20-fold increases observed in CYP1A1 (Stresser
etal., 1994). Chronic exposures, as studied in the current experiment, resulted in
even stronger 40- and 30- fold inductions for CYP1A1 and CYP3A2, respectively
(Leibeltetal., 2003a; Leibeltetal., 2003b). Sub-chronic exposures to 13C have
also been shown to inhibit FMO expression and activity in the rat in a time- and
dose-dependent fashion (Larsen-Su and Williams, 1996). For drugs metabolically
inactivated by FMO a trend of increasing efficacy or toxicity could occur with
increasing exposure to 13C or DIM, whereas the opposite could occur with CYP
induction as an increase in metabolism could lead to diminished potency.
The potential effects that the combined CYP induction and FMO inhibition
have on drug metabolism were documented by Katchamartetal. (2000). This114
study demonstrated that the ratio of FMO/CYP mediated metabolismof N,N-
dimethylaniline, nicotine, and tamoxifen in incubations with livermicrosomes
decreased after rats were administered 2500ppm DIM in their diets for 4 weeks.
This decrease in metabolite ratiowas attributed to an inhibition of hepatic flavin-
containing monooxygenase isoform 1 (FMO 1)-dependent formation ofthe N-oxide
with a concurrent induction of CYP-mediated N-demethylation.
Precision-cut liver slices have become widely acceptedas a suitable in vitro
tool to address questions regarding drug metabolism, and the inductionproperties
of drugs and xenobiotics (Miller et al., 1993; Lake et al., 1996; Edwardset al.,
2003). Liver slices have the advantageover other in vitro systems in that the
structural integrity of the organ, the cell heterogeneity and the cell-cell interactions
are retained (Parrish et al., 1995). Numerous studies have confirmed the reliability
of slices in mimicking in vivo conditions and slices have been shownto up-regulate
CYP expression in response to chemical treatmentsas observed in studies
employing inducers such as-naphthoflavone, phenobarbital, rifampcin, and 13C
(Ekins et al., 1995; Oganesian et al., 1997; Renwick et al., 1999; Edwardset al.,
2003). Radiolabelled ligand metabolism and fate studies have verified the ability of
slices to metabolize compounds ina way consistent with in vivo metabolism (Price
et al., 1995; Ball et al., 1996; Worboys et al., 1996).
The aim of the current studywas to investigate the effects that chronic
exposure to 13C and DIM and subsequent enzyme modulation may have on115
druglxenobiotic metabolism utilizing the rat liver slice model. Consideringresults
from previous studies, it would be expected that incubations ofa xenobiotic, that is
substrate for both CYP and FMO, with slices from rats exposedto 13C and DIM
would result in altered metabolism in favor of higher CYP mediatedmetabolism.116
Materials and Methods
Chemicals
Indole-3-carbinol (13C) and [U-14C] N,N-dimethylaniline (DMA) (15.5
tCi/j.imo1) were obtained from Sigma-Aldrich Co. (Milwaukee, WI).3,3'-
Diindolylmethane (BioResponse D1MTM)was provided by BioResponse, LLC
(Boulder, CO).
Animals
Six male Sprague-Dawley ratswere purchased from Simonsens (Gilroy,
CA) at four weeks of age. After aone week acclimation period, animals were
randomly divided into 3 different treatmentgroups. Rats were housed individually
in hanging metal wire cages at the Laboratory Animal Resource Center,Oregon
State University and maintained at 22°C and 40 to 60 % humidityon a 12 hour
light/dark cycle. Both tap water and powdered semisynthetic dietwere available ad
libitum throughout the study. Group 1 received control (AIN-76A) diet. The diet
for groups 2 and 3 were supplemented with 13Cor BioResponse DIMTM to levels
providing a dose of 50 mg/Kg/dayor 66 mg/Kg/day, respectively. Rats were
weighed and food consumption estimated weekly for the first three months and
monthly thereafter. At the end of one year all dietswere removed overnight before
sampling. Rats were anesthetized and then euthanized by exsanguination according
to a protocol approved by the Oregon State University Institutional Animal Care
and Use Committee.117
Sample Collection and preparation
The liver was removed from each animal and stored in ice cold Waymouth
MB 752/1 medium (Sigma-Aldrich) supplemented with 10 mM HEPES, 8 mlvi
sodium bicarbonate, 50 mg/mi gentamicin and 10% fetal calfserum. All media
were filter-sterilized, using a 0.22 tm Gelman Vacucap filter (Fisher Scientific)
into sterile containers and stored at 4°C. Thesame media were used for
transportation of livers, slice preparation, and incubation. All glassware and
equipment was sterilized at 105°C for 30 minutes prior touse.
High-precision liver slices
Using a stainless steel tissue coringpress, 8 mm cores were generated from
the largest lobe of each rat liver and then cut into precision slices (250m in
thickness) using a Krumdieck tissue slicer (Alabama Research and Development
Corp., Munford, AL). The slices were distributed into 12-well Falcon plates (one
slice per well) in triplicate, containing 1 ml of the previously described Waymouth
media per well. Additional slices were distributed to separate plates foruse as
controls and for the ATP assay described below. All plateswere covered and
preincubated for 1 hour inside a tight-seal container saturated with 95%02/ 5%
CO2. Containers were kept inside an incubator at 34°Con an orbital shaker set at
I1jI118
DMA incubations
After 1 hour preincubation, slices were transfered to new plates containing
100 M ['4C] -DMA and incubated for an additional 30 minutes. [14C] -DMA was
added to Waymouth media, prior to introduction of slices, using dimethylsulfoxide
as a vehicle (0.5% of final volume) for a final volume of 1 ml per well. After 30
minutes both media and slice were removed from the well for extraction.
Extraction
An equal volume (1 ml) of cold methanol was added to media samples from
each well and spun at 10,000 g in a table top centrifuge for 5 minutes at 4°C to
precipitate protein. The supernatant was removed for HPLC analysis.
The triplicate slices from each rat were pooled and then homogenized in 500l
phosphate buffer containing 30% glycerol, 1mM EDTA, 1 mM dithiothreitol, 0.1
mM phenylmethylsulfonylfiouride, pH 7.4. An equal volume (0.8 ml) of cold
methanol was added and the samples spun at 10,000 g in a table top centrifuge for 5
minutes at 4°C. The supernatent was removed for HPLC analysis.
HFLC analysis
FMO and CYP activity toward ['4C] -DMA was determined utilizing an
HPLC assay to simultaneously measure metabolites formed by either FMO-
mediated N-oxygenation or CYP- mediated N-demethylation (Williams, 1991;
Shehin-Johnson et al., 1995) (Figure 4.1). Samples from media and slice
homogenates were transferred to autosampler vials and placed in the sample119
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Figure 4.1: Metabolism of N,N-dimethylaniline. N-oxygenation by flavin-
containing monooxygenase (FMO) and N-demethylation by cytochrome P450
(CYP).
compartment (maintained at 10°C) of the Waters 2690 HPLC (Milford, MA).
Chromatography of the samples was performed usinga 4.6 mm X 10 cm Whatman
RAC II Partisjl 5-ODS 3 column (Fisher Scientific) ina 35°C, temperature-120
controlled compartment. Elutionwas performed using 62% methanol: 38% water
with a constant flow rate of 0.5 mi/minute. Bothan inline Packard TR505
radiometric detector (0.5 ml cell, 1.5 ml/min scintiiiant) anda Waters 996
Photodiode Array detector were used for detection. Relative retentiontimes of
DMA (7-8mm.),methylaniline (4-5 mm.), and DMA N-oxide (2-3 mill.)are
demonstrated in a representative chromatogram trace (Figure 4.2).
44
(mir
Figure 4.2: HPLC chromatogram demonstrating separation of DMA (retention
time=7.4 minutes), methylaniiine (4.7 minutes) and DMA N-oxide (2.7 minutes).121
A TP assay
At time 0 and after final incubation, ATP productionwas used as a marker
to test for cell viability and signs of cytotoxicity. ATP productionwas measured
using kits purchased from Sigma Chemicals basedon a procedure described by
Adam (1963).122
Results
The viability of slices was assessed by analyzing ATP levels in slice
homogenates before treatment and after incubation with DMA. No signs of toxicity
were observed as post-incubation ATP levels were higher than in fresh timeO
control slices (Figure 4.3).
Figure 4.3: ATP levels in slice homogenates as a measure of viability after
incubation with DMA. Expressed as % of ATP level found in fresh control slices.
Values represent group averages ± SE.
The effects of chronic 13C and DIM treatment on CYP and FMO enzyme
levels were assessed indirectly by quantitation of metabolites formed during the
incubation with DMA of slices from rats exposed to 13C and DIM. Due to the lack
of metabolites present in media, only homogenate samples were considered in123
calculations of total metabolite percentages (Figure 4.4). When slices from control
rats were incubated with DMA approximately 90 % of the total metabolites formed
as a result of FMO mediated N-oxygenation and approximately 10 % of the total
metabolites resulted from N-demethylation by CYP. In incubations with slices
from 13C treated rats, the percentage of metabolites formed from each pathway was
approximately 50 %. Slices from DIM treated rats produced levels of metabolites
intermediate to those seen in the control and 13C treated animals with 80 and 20 %
of the total metabolites resulting from N-oxygenation and N-demethylation,
respectively.
90
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Figure 4.4: Percentage of total DMA metabolites produced from FMO N-
oxygenation and CYP N-demethylation after incubation with liver slices from rats
fed control diet or diet containing 13C or DIM for 1 year. Values represent group
averages ± SE.124
Discussion
Confirmation of cell viability isnecessary in slice experiments to determine
the extent of structural or biochemical damage thatmay introduce confounding
variables to the model system. Histological assessment of slice viabilitywas not
performed in this study, as previous studies have shown the ATPassay to
accurately predict the percentage of living cells (Oganesianet al.,1997; Shilling
and Williams, 2000). The post-incubation increase in cellular ATP levels in slices
from all treatment groups confirms slice viability and indicates that the metabolic
differences observed in this studycan be attributed to enzyme activity and not
toxicity. A post-incubation increase in ATP levels is also consistent with previous
slice studies where it was observed that tissue slices take timeto fully recover from
processing.
Based upon the results of previous studies,we postulated that chronic
dietary exposure to 13C and DIM could significantly alter the metabolic profile of
drugs that are substrates for bothmonooxygenase systems. While not a
pharmaceutical, DMA was a good candidate forour model system because of its
previously characterized co-metabolism by CYP and FMO (Katchamartet al.,
2000). Tn this study most of the contribution fora shift in DMA metabolism
appeared to come from an increase in CYP metabolismas opposed to a decrease in
FMO metabolism, and DiM appeared to be less potent at altering the metabolic
profile. This is consistent with unpublished data fromour lab indicating that the125
inhibition of FMO by 13C observed in short-term studies in the rat does not
continue with chronic exposure, and in fact after 6 and 12 months of exposure to
13C the FMO levels return to that of untreated rats. The results are also consistent
with a previous study demonstrating that CYP levels are highly inducible after
chronic exposure to 13C, whereas DIM appeared to be a less efficacious inducer
(Leibeltet al.,2003). Independent of whether the change in metabolism came from
a decrease in FMO mediated metabolism or an increase in CYP contribution, the
marked shift in metabolism may result in significant changes to the toxicological
and therapeutic properties of drugs.
Whether these findings can be extrapolated to humans depends on the
similarities for regulation of these monooxygenase systems between the two
species. While a comparable induction pathway of CYP in humans and rats
mediated by the AHR is well documented, FMO responses are less well known.
The major FMO in adult humans is FMO3 rather than FMOI. Human FMO1 is
predominantly expressed in fetal liver and adult kidney. Previous studies have
demonstrated a decrease in FMO3 activity towards trimethylamine in humans after
being fed 300 g/day of Brussels sprouts, providing 0.002-0.014 mmol 13C/Kg!day
(Cashmanet al.,1999). However, Brussels sprouts also contain numerous other
phytochemicals like isothiocyanates and dithiolanes that may affect FMO levels and
activity.126
While the focus of this study has beenon the effects of chronic exposure to
13C and DIM on drug metabolism, the observed shift in metabolismobserved could
also be important in carcinogen bioactivation and detoxification. In general,FMOs
produce fewer bioactivated products than CYP (Cashman, 1995). This is especially
relevant for CYPs of the 1 A subfamily, given the role of theseenzymes in
activation of polycyclic aromatic hydrocarbons suchas benzo[apyrene, and
aromatic amines such as 4-aminobiphenyl and PhIP.
In summary, we have demonstrated that chronic oral administration of 13C
and DIM to rats markedly alters the in vitro metabolism of DMA,a substrate for
both CYP and FMO monooxygenases. Itappears that the majority of this
metabolic difference can be attributed toa strong induction of CYP that is
consistent with 13C being a more efficacious inducer of CYP than DIM. The
results of this study are important to human healthas 13C and DIM are now
marketed as supplements and proposedas chemopreventive agents for estrogen-
dependent cancers. These compounds could be capable of causing metabolic
alterations in humans similar to those observed in rats in this study, leadingto
effects on therapeutic efficacy or toxicity. Further studies need to be completedto
determine the potential for a similar response in humans.127
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CHAPTER 5
The Effects of Strain on 13C Tumor Modulation in the Mouse
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Abstract
Jndole-3-carbinol (13C), a naturally occurring dietary component found in
cruciferous vegetables, has demonstrated chemoprotective properties in a number
of animal studies. 13C is currently marketed as a dietary supplement and is under
investigation as a chemopreventive agent against breast cancer, despite evidence
that this compound is also capable of promoting hepatocarcinogenesis in some
cancer models. In the current study, the infant mouse model was used to further
elucidate whether 13C modulates carcinogenesis via estrogenic pathways. Infant
male mice of a strain in which estrogens inhibit liver cancer (C57BL/6J, black) and
a strain in which estrogens do not inhibit liver cancer (C57BR/cdJ, brown) were
initiated with 5 mg/kg diethylnitrosamine (DEN), by i.p. injection, at 15 days of
age. Nine days after initiation mice were weaned and immediately put on control
diet or diet containing 1500 ppm 13C. After seven months, whole body and liver
weights were recorded and the livers were sampled for tumors. A significant strain
difference in sensitivity to DEN-initiated hepatocarcinogenesis was observed. 13C
exposure resulted in a significant reduction in body weights for black mice initiated
with DEN. 13C exposure did not influence body weight in brown mice but a
significant increase in liver somatic index due to large tumor volumes was observed
in brown mice initiated with DEN. 13C treatment did not result in significant tumor
modulation in brown mice and with the exception of two mice that had unusually
high tumor burdens (50-60x the next highest value), 13C treatment resulted in133
approximately a 3-fold reduction in tumor multiplicity and volume in black mice.
The results of this study suggestan estrogenic mechanism of tumor modulation by
13C in mice.134
Introduction
Indole-3-carbinol (13C) is a naturally occurring plant alkaloid formed from
the hydrolysis of indole glucosinolate (glucobrassicin), found in significant
concentrations in cruciferous vegetables suchas broccoli, cauliflower, and Brussels
sprouts (Slominski and Campbell, 1987; McDannell et al., 1988). Glucobrassicin
is hydrolyzed to glucose, sulfate, thiocyanate and 13Cupon maceration of plant
tissue at neutral pH, in the presence of theenzyme myrosinase. In an acidic
environment, such as the stomach after oralexposure, 13C undergoes rapid
oligomerization to form condensation products (13C-ACP's) including 3,3'-
diindolylmethane (DIM), 2-(indol-3-ylmethyl)-3 ,3 '-diindolylmethane (linear trimer
or LT1), 5,6,1 1,12,17,18-hexahydrocyclonona[l,2-b:4,5-b':7,8-b"]triindole (cyclic
trimer or CT) and indolo[3,2-b]carbazole (ICZ) (Bjeldaneset al., 1991; De Kruifet
al., 1991; Wortelboer et al., 1992). It is through interactions of ACP's with the aryl
hydrocarbon receptor (AHR) that 13C is believed to produce the majority of its
effects, which have been proposed to include both chemoprevention andtumor
promotion.
It was initially demonstrated that 13C and other indoleswere
chemoprotective when administered concurrently with the carcinogenor prior to
initation (Wattenberg, 1977). Since then, 13C and DIM have been shown to be
chemoprotective in a number of animal models anda variety of target organs
(Morse etal., 1990; Bailey et al., 1991; Kojima et al., 1994; Grubbset al., 1995;135
Guo et al., 1995; Oganesian et al., 1997; Jin et al., 1999; Chenet al., 1998;
Srivastava and Shukla, 1998). However, subsequent research demonstrated that
chronic post-initiation exposure to J3C could potentially enhance carcinogenesis
and result in significant promotion of liver tumors in rats and trout (Dashwoodet
al., 1994; Kim et al., 1994; Oganesian et al., 1999; Stoneret al., 2002).
Alteration of estrogen metabolism and the estrogen signal transduction
pathway is one of the proposed mechanisms by which 13C could modulate
carcinogenesis (Bradlow et al., 1991; Baldwin and LeBlanc, 1992; Niwaet al.,
1994). Through the AHR, 13C has been shown to inducea number of phase I
enzymes including cytochrome P450 (CYP). CYP1A1 and 1A2 catalyze the 2-
hydroxylation of J3-estradiol (B2) and the shift towards higher levels of 2-hydroxy-
B2may explain the chemoprotective effect exhibited by 13C or DIM against
estrogen dependent cancers (Bradlow et al., 1991; Jellinck etal., 1993; Telang et
al., 1997; Wong et al., 1997; Michnovicz, 1998). Other examples of antiestrogenic
effects from 13C and 13C ACP' s include the antiestrogenic properties of DIM in
MCF-7 cells (Chen et al., 1998) andLT1functioning as an estrogen receptor
antagonist in human breast cancer cell lines (Chang et al., 1999). Conversely, 13C
and 13C ACPs have been shown to exhibitsome estrogenic activity as observed in
the rainbow trout model (Shilling and Williams, 2000; Shillinget al., 2001), and as
an estrogen receptor agonist in human breast cancer cells (Riby et al., 2000). An
alternative mechanism for pro-estrogenic effects of 13C could be through induction136
of CYP 19 (aromatase) resulting in enhanced synthesis ofestrogens (Sandersonet
al., 2001). Through estrogenic properties, 13C could enhance carcinogenesisby
promoting estrogen dependent tumors.
In summary, it has been established that 13C and 13C-ACP'scan have both
estrogenic and anti-estrogenic characteristics andcan act to both inhibit and
promote carcinogenesis. It has also been demonstrated that the effects that
estrogens have on carcinogenesis are species and tissue specific,as estrogens
promote liver cancer in the rat (Yager and Yager, 1980; Wanless and Medline,
1982) while inhibiting chemically induced liver tumors in mice (Poole and
Drinkwater, 1996). In the mouse, there is alsoa strain-dependent response to
estrogens as modulators of liver cancer (Poole and Drinkwater, 1996). 13C shows
similar characteristics as it is known to promote livercancer in rats (Stoneretal.,
2002) and trout (Oganesianetal., 1999) and inhibit DEN- induced
hepatocarcinogenesis in C57 black mice (Oganesianetal., 1997). 13C has also
been shown to be estrogenic in trout (Shilling and Williams, 2000; Shillingetal.,
2001). This evidence indicates that 13C is most likelya modulator of liver cancer
via estrogenic pathways. If this hypothesis is correct, then liver tumor formation
will be inhibited by 13C feeding in amouse strain that is estrogen responsive
(C57BL/6J) and tumor formation should not be affected by 13C feeding ina mouse
strain that is non-responsive with respect to liver cancer (C57BR/cdJ).137
Materials and Methods
Chemicals
Diethylnitrosamine (DEN) and indole-3-carbinolwere purchased from
Sigma Chemical Co. (St. Louis, MO).
Animals
C57BL/6J (black) and C57BR/cdJ (brown) micewere purchased from
Jackson Laboratory (Bar Harbor, ME)as litters (10 litters per strain), each
containing 5 male pups. All experimental procedureswere conducted according to
a protocol approved by the Oregon State University Institutional Animal Care and
Use Committee.
Animal Treatment and Diets
At 15 days of age mice were injected i.p. with 5 mg/kg DEN in saline. DEN
stock concentrations were prepared such that for eachgram of body weight mice
received 10 ul stock solution or saline for controls. Theaverage body weight at day
15 was 5 grams. Nine days after injection micewere weaned and experimental
diets started immediately.
Mice from each strain were divided into 4 treatmentgroups (Table 5.1). Groups 1
and 2 consisted of non-initiated (saline injected) animals, and received either
control diet or diet containing 1500 ppm 13C, respectively. Groups 3 and 4
consisted of initiated (DEN injected) animals and also received either control diet
or diet containing 1500 ppm 13C, respectively. For the brown mice, groups 1 and 2138
consisted of 13 mice, and groups 3 and 4 consisted of 14 mice. Forthe black mice,
groups 1 and 2 consisted of 12 mice, and groups 3 and 4 consisted of 17 mice.
Prior to the completion of the study, two animals from browngroup 1, one animal
from brown group 2, one animal from browngroup 3 and one animal from black
group 2 died for reasons that were not related to treatment.
Diet preparation
A1N76A semipurified rat/mouse diet containingno synthetic antioxidants
(butylated hydroxyanisole or butylated hydroxytoluene)was prepared using
components from JCN (Costa Mesa, CA). 13C diets were preparedonce per week,
by adding 13C in powdered form to control diet, and storingat 4°C until used.
Animal Husbandry
Mice were kept at the Laboratory Animal Resource Center, Oregon State
University, and maintained at 22°C and 40 to 60 % humidityon a 12 hour
light/dark cycle. Lactating females with litterswere housed in plastic cages with
polyurethane covers. Pups remained with the mother until weaning (day 24). Once
weaned, mice were housed one per cage, with diet and water availablead libitum.
Mice were weighed weekly for the first three months and then hi-monthly
thereafter.139
Necropsy
After 7 months on experimental diets, micewere weighed and euthanized
byCO2asphyxiation. Livers were removed, weighed and examined
macroscopically for tumors. Tumors> 0.5mm in diameter were counted.
Statistics
Data were analyzed separately for brown and black mice. Body weight,
liver somatic index and total tumor volume datawere analyzed on the log
transformed scale, while tumor multiplicity datawere analyzed on the square root
transformed scale. The transformations resulted in approximately normal and
homogeneous errors. Linear mixed modelswere used that included, when
necessary, random additive and non-additive (litter by treatment interaction) litter
effects. Analyses were conducted using the Mixed Procedure in SAS version 8.2
(SAS Institute, Cary, NC (2001).140
Results
Body Weight
At the conclusion of the study the average body weights for black and
brown mice in the control groups were37.5and53.9grams, respectively (Table
5.1). 13Cdid not appear to have an effect on average body weight with the
exception of causing a significant reduction to an average of35.3grams in black
mice initiated with DEN (P=O.0032) (Figure5.1).13C did not contribute to any
weight reduction in brown mice and despite a noticeable difference in the body
weights of brown mice initiated with DEN, no significant difference was observed
due to a large variation in response between litters (Figure5.2).
TABLE5.1.STUDY DESIGN AND DATA SUMMARY
Group DEN
(mg/kg)
13C
(ppm)
Final
Body wt
(g)
Liver wt
(% of body
wt)
Tumor
Incidence
Total tumor
volume per
mouse
Brown 1 0 0 53.9±2.2 5.13±0.22 0/11 0
Brown 2 0 150051.6±2.1 5.46±0.30 0/12 0
Brown 3 5 0 43.2±0.710.90±0.89* 13/13 8485±1542
Brown4 5 150042.4±1.311.76±1.16* 14/14 15375±3052
Black 1 0 0 37.5±1.2 5.00±0.41 0/12 0
Black 2 0 150037.0±0.7 5.60±0.23 0/11 0
Black 3 5 0 39.5±1.1 5.78±0.16 14/17 39.6±9
Black 4 5 150035.3±1.0*5.72±0.20 14/17 824±551
(12.1±4.2)1*
All data given are means ± standard enors.
*= significantly different from corresponding control group,P <0.05
1mean and standard error with exclusion of outliers.141
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Figure 5.1: Body weights in black mice givenan i.p. injection of either saline or 5
mg/kg DEN and then fed control diet or diet containing 1500ppm 13C for 7
months. * = significantly different from corresponding controlgroup, P< 0.05.
60-
50Till"
roiiet 40 44*44*44*
..,,......, ...,.......
g 13C 2'
c,30
DEN >' 4*44*
20
____________
10-.----
0 44*
Treatment
Figure 5.2: Body weights in brown mice givenan i.p. injection of either saline or S
mg/kg DEN and then fed control dietor diet containing 1500 ppm 13C for 7
months. Reductions in DEN initiated micewere not significant due to litter effects.142
Liver Somatic Index
The liver somatic index of black micewas unaffected by 13C or DEN
exposure in this study despite the presence of tumors in DEN initiated mice (Figure
5.3). Due to the extent of tumors observed in the brown mice exposedto DEN, and
despite the previously mentioned effects that litter hadon body weight, the liver
somatic index in initiated mice was significantly higher (P=0.002) than observed in
the corresponding control groups (Figure 5.4).
Tumor Incidence
Tumor incidence was not affected by chronic post-initiationexposure to 13C
in either strain of mice (Table 5.1). In brown mice initiated with DEN,tumor
incidence was found to be 100% in mice fed control diet (13 of 13)or diet
containing 1500 ppm 13C (14 of 14). Thegroups of black mice that were initiated
with DEN and either fed control dietor diet containing 1500 ppm 13C both had an
82.4 % incidence (14 of 17). No tumorswere observed in non-initiated mice of
either strain.
Tumor Volume
The total tumor volume for each mousewas calculated from the diameter
measurement of each tumor by assuming the tumors were spherical (Table 5.1). In
brown mice, feeding 13C enhanced tumor volume 1.8-fold but this did not reach
statistical significance (p=O.O6, simple t test). Ifone takes into account litter
effects, there is little evidence of an effect of 13Con tumor volume in brown mice.143
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Figure 5.3: Liver somatic index in black mice.
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Figure 5.4: Liver somatic index in brown mice. *significantly different from
corresponding control group, P <0.05.144
In the black mice no litter effectswere observed. If one considers all mice, there is
an apparent 20-fold enhancement of tumor volume by the 13C diet. If the two mice
with massive tumor volumes (50-60x next highest value)are considered outliers,
13C treatment results in an almost 3-fold reduction in tumor volume (p<O.O5).
Tumor Multiplicity
Figures 5.5 and 5.6 display tumor multiplicity data for black and brown
mice, respectively. 13C did not have a significant effecton tumor multiplicity in
brown mice regardless of litter effects. If all black miceare considered, the small
reduction in average tumor number, from 7.1 to 4.7, observed in mice fed 13C is
also insignificant. As observed for the tumor volume data, if the two mice with
extreme tumor burden are considered outliers, 13C treatment results inan almost 3
fold reduction in tumor multiplicity to 2.7 tumorsper mouse (p<0.05). Brown mice
were an order of magnitude more sensitive to DEN and had on average 90.2 and
82.8 tumors for the control and 13C treated mice, respectively.145
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Figure5.5:Tumor multiplicity in black mice initiated with DEN and fed either
control diet or diet containing1500ppm 13C. No tumors were observed in non-
initiated mice. *p<005
Figure5.6:Tumor multiplicity in brown mice initiated with DEN and fed either
control diet or diet containing1500ppm 13C. No tumors were observed in non-
initiated mice.146
Discussion
The purpose of this study was to investigate the mechanism by which
chronic dietary post-initiation exposure to 13C inhibits hepatocarcinogenesis in
mice (Oganesian etal.,1997) while promoting liver tumors in rats (Stoneret al.,
2002) and trout (Dashwoodet al.,1994, Oganesianet al.,1999). Interestingly,
estrogens promote liver cancer in rat (Yager and Yager, 1980; Wanless and
Medline, 1982), and trout (Nunezet al.,1989) but function as inhibitors inmost
strains of mice (Poole and Drinkwater, 1996). This finding, along with evidence
that 13C is estrogenic in trout (Shilling and Williams, 2000; Shillinget al.,2001)
indicates that 13C maybe modulating liver tumors via an estrogenic mechanism.
Two different strains of mice were utilized in this study in an attempt to
clarify this issue. C57BL/6J (black) mice were selected as an estrogen responsive
strain in which suppression of liver tumor development by estrogens is observed.
C57BR/cdJ (brown) mice provided a non-responsive mouse model in which
estrogens do not influence hepatocarcinogenesis (Poole and Drinkwater, 1996). If
13C were modulating hepatocarcinogenesis by estrogenic mechanisms then the
inhibition of liver tumors previously observed in black mice exposed to 13C would
not be observed in brown mice exposed to the same treatment.
The large discrepancy in sensitivity to DEN between the black and brown
mice observed in this study was not expected. Female brown mice are known to be
more susceptible to hepatocarcinogenesis because they are highly insensitive to the147
suppressing effects of ovarian hormones suchas estrogen but the male brown mice
used in this study are intermediate in sensitivityamong inbred mouse strains (Poole
and Drinkwater, 1996).
In this study, 13C treatment did not havea significant influence on tumor
modulation in brown mice, despite resulting ina I .8-fold enhancement in total
tumor volume per mouse. The 3-fold reduction in tumor multiplicity andaverage
total tumor volume observed in black mice is consistent witha chemopreventive
effect of 13C previously observed in thissame C57BL/6J infant mouse model with
DEN initiation (Oganesian et al., 1997). The slight but insignificant increase in
tumor volume in brown mice along with the reduction in tumor multiplicity and
volume in black mice supports the hypothesis of 13C actingas an estrogen. This
could be significant for determining the suitability of 13C supplementation in
humans for preventing estrogen-related disease without increasing the risk of
hepatocarcinogenesis.148
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Summary and Conclusions
Indole-3-carbinol (13C) and 3,3'-diindolylmethaneare rapidly becoming two of
the top selling phytochemical supplements andare under investigation as potential
chemopreventive agents, in spite of limited informationon the effects of chronic
exposure. Previous studies have demonstrated that the chemopreventive potential of
13C and DIM in animal studies is dependenton species, strain, tissue and timing of
treatment relative to carcinogen exposure. The majority of biological effects from 13C
are the result of DIM and other 13C-ACPs binding to the aryl hydrocarbon receptor and
the subsequent induction of phase I and phase IIenzymes. The levels of these enzymes
can readily influence carcinogenesis by blocking the action of carcinogens or increasing
their rate of bio activation. Modulation ofenzyme levels can also result in altered
metabolism of compounds that could affect efficacy and toxicity of pharmaceuticals and
xenobiotics. The current work focusedon the effects of chronic dietary 13C and DIM
exposures on health, drug metabolism and carcinogenesis in rodent models.
The only sign of toxicity from either compoundwas a reduction in body weight
in Fischer 344 rats treated with 2500ppm dietary 13C for 12 months. Toxicity was not
confirmed by blood chemistry or histopathological analysis and, furthermore,no
toxicity was observed in Sprague-Dawley rats aftera comparable exposure. In fact, a
general decrease in serum enzyme levels in male rats of both strainsmay point towards
a potential protective effect from age related tissue damage.154
Previous studies have demonstrated that both 13C and DIM are capable of
modulating the levels of monooxygenase enzymes and therefore have the potential to
alter in vivo drug metabolism. This was confirmed by the current work in which
chronic exposures to 13C and DIM resulted in significant induction of total hepatic
cytochrome P450 (CYP). CYP1A and CYP3A were induced up to 80- and 30- fold,
respectively, depending on the strain of rat and length of exposure. DIM was a less
efficacious inducer of CYP and also caused less modulation to drug metabolism in liver
slice incubations.
As previously observed, chronic post-initiation exposure to 13C resulted in an
apparent chemoprotective effect against DEN initiated hepatocarcinogenesis in black
mice. Alternatively, tumor size, incidence, and multiplicity were not significantly
altered by 13C exposure in brown mice. These results suggest that 13C modulates
hepatocarcinogenesis in mice via an estrogenic mechanism.
These studies demonstrate that chronic 13C and DIM exposures do not produce
appreciable direct toxicity in rodents, but adverse effects related to exposure could
occur through indirect mechanisms. Chronic post-initiation exposure did not result in
tumor promotion in this study but the observed induction of CYP 1A has been linked to
increased cancer risk through greater carcinogen bioactivation. The alterations in
monooxygenase levels and the associated effects on metabolism confirm our concern
that chronic 13C and DIM exposure may result in significant effects on drug and/or
xenobiotic metabolism.155
The results of the current work, along with previous studies demonstrating that
13C causes toxicity in some models and can promote tumors, brings into question the
benefit versus risk that comes from 13C and DIM supplementation. If results from these
studies in rodents, following chronic exposure of 13C and DIM, are indicative of the
human response then direct toxicity from long-term supplementation in humans should
not be the foremost concern. The major implications for human health would be
possible alterations in drug and/or xenobiotic metabolism that could lead to drug
interactions or induction of carcinogenesis. These risks, in addition to the previously
mentioned work that demonstrated the lowest dose of 13C to inhibitmammary tumors
in the rat was potent enough to induce lesions in the liver, indicate that the effect of
chronic supplementation with 13C and DIM in humans maybe too uncertain for
preventative use. Conversely, if trials of 13C and DIM as treatments for estrogen
dependent disease like RRP and CIN are successful, the benefit of long-termexposure
would in this case overcome therisk.Additional studies should be completed to further
determine the effects of chronic exposure to 13C and DIM in humans.156
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